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ABSTRACT 
 
DIRECT ASSESSMENT OF RESPIRATORY AND CARDIAC 
FUNCTION AND RESERVE CAPACITY IN A LARGE ANIMAL 
MODEL OF DUCHENNE MUSCULAR DYSTROPHY. 
 
Andrew Frederick Mead 
Hansel H. Stedman, M.D. 
Duchenne muscular dystrophy (DMD) results in a progressive loss of cardiac and 
respiratory reserve capacity that is ultimately fatal. Although the molecular deficiency 
that causes DMD is known, the systemic nature of the disease - along with issues of 
patient safety - have prevented the direct measurement of reserve and hindered our 
understanding of the precise mechanisms involved in the functional decline of these two 
systems. The golden retriever muscular dystrophy (GRMD) dog is an important single-
gene animal model of DMD, which exhibits the major functional and cellular hallmarks of 
the human disease, including progressive loss of respiratory and cardiac function. Here 
we use surgical and pharmacological techniques to isolate both systems from the 
confounding influence of background disease, and measure function and reserve 
directly. We show that cardiac reserve declines as a result of diastolic and systolic 
dysfunction that is independent of cardiac myocyte necrosis. In the respiratory system 
we find that the diaphragm undergoes a dramatic process of remodeling that serves to 
enable the compensatory use of other muscle groups to facilitate breathing, and to 
protect against energetically unfavorable chest wall motion. Our results shed light on the 
decline of two muscle-driven systems crucial for life. In addition to providing much 
needed endpoint measures for assessing the efficacy of therapeutics, we expect these 
findings to be a starting point for a more precise understanding of cardiopulmonary 
failure in DMD. 
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Introduction 
 
Duchenne muscular dystrophy (DMD) is a complex and devastating disease of muscle 
caused by a single gene defect. The absence of a functional dystrophin protein, by way 
of an inherited or de novo mutation in its gene, results in widespread pathology of all the 
body’s muscles (Hoffman, Brown & Kunkel 1987). Though pathology varies among 
muscles of differing function and use, this pathology is typified by repeated cycles of 
necrosis and regeneration of muscle fibers, and by progressive replacement of muscle 
by fatty and fibrous tissue. Boys with DMD are usually diagnosed between the ages of 
two and four years, when they present with a number of hallmark symptoms, including 
proximal limb weakness. From there, weakness progresses rapidly, and by age 10-13 
almost all boys lose the ability to walk. By the late teens most boys will require 
respiratory support as the muscles of the respiratory pump become unable to provide 
adequate ventilation (Birnkrant et al. 2010). Although recent improvements in palliative 
care have extended the life expectancy somewhat, few young men live past their 
twenties. DMD is the most common lethal inherited disease in man, affecting roughly 
one in 3500 newborn males (Dooley et al. 2010). 
Although today the clinical course of the disease is well described, as is the 
nature of the molecular deficiency, a major challenge has been assessing the chain of 
causation that leads from the initial insult to the complex clinical pathology that results. 
The work in this thesis takes advantage of an important canine model of the disease, 
and focuses on observations of dysfunction at the level of the muscle-driven organ 
system in order to draw connections between cellular and clinical pathology. 
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A molecular deficiency. 
 
When the dystrophin gene was eventually cloned, the field was surprised that none of 
the major high-abundance proteins of the contractile apparatus were responsible for the 
disease (Hoffman, Brown & Kunkel 1987, Monaco et al. 1986). Instead, the product of 
the DMD locus was a protein present at roughly 1/25000th the concentration of myosin, 
Figure 1. A schematic representation of dstrophin and members of the dystrophin-
related glycoprotein complex (DGC) in the cell. The N-terminal of dystrophin binds f-
actin.  The C-terminal region of dystrophin binds to the DGC. Adapted from Barresi et 
al. 2006.  
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and localized at the sarcolemma (Campbell, Kahl 1989, Watkins et al. 1988). The 
dystrophin gene, at 2.4 million base pairs, is by far the longest gene in the human 
genome. Its extreme size is thought to contribute to the high incidence of DMD, as 
deletions that would elsewhere affect multiple genes can fit entirely within the dystrophin 
locus (Monaco, Kunkel 1988). The gene’s largest protein product, dp427, commonly 
referred to as dystrophin, consists of a long chain of spectrin-like triple-helical repeats 
connecting two binding domains. Mutations that take out a number of these spectrin-like 
repeats, but preserve the gene’s reading frame result in a milder muscular dystrophy: 
Becker muscular dystrophy (BMD) (Monaco, Kunkel 1988, Koenig et al. 1989).  
The N-terminal region of dystrophin binds cytoskeletal γ-actin at the costamere 
(Rybakova, Patel & Ervasti 2000). The cysteine-rich C-termial region binds to 
βdystroglycan, which nucleates a large trans-membrane spanning complex, the 
dystrophin associated glycoprotein complex (DGC), which in turn binds proteins of the 
basement membrane and extracellular matrix (ECM) through laminin (Fig 1.) (Campbell, 
Kahl 1989, Ervasti, Campbell 1993). In the absence of dysrophin, the DGC is reduced at 
the membrane, and a link to the ECM is largely lost. Several forms of muscular 
dystrophy are caused by mutations in other members of the DGC, as well as laminin, 
and collagen VI (Kanagawa, Toda 2006). Although it’s location near the sarcolemma, 
and loss of sarcolemmal stability in its absence suggested such a role (Karpati, 
Carpenter 1986, Menke, Jockusch 1991), 1993 Petrof et al first demonstrated that 
dystrophin protects the sarcolemma from injury during forceful contractions (Petrof et al. 
1993a). The precise mechanism by which the DGC prevents failure of the muscle cell 
membrane (sarcolemma) is complex and still not fully understood. However, the 
consensus view is that the initial insult to a dystrophin-null myofiber comes in the form of 
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local contraction-induced sarcolemmal rupture leading to the influx of calcium ions, 
which in turn trigger further local crossbridge activation, and necrotic signaling pathways 
within the cell (Petrof et al. 1993b, Claflin, Brooks 2007). 
 
Treatments. 
 
Current treatment for DMD is, for the most part palliative, and targets 
pathological aspects of the disease that are downstream of the molecular deficiency. 
Pharmacological treatment of DMD is limited to the use of systemic corticosteroids to 
minimize inflammation and delay fibrosis. The benefits are small but measurable, but the 
side-effects often preclude sustained use (Moxley et al. 2010). Progression of the 
disease in postural musculature commonly leads to severe scoliosis with adverse effects 
on cardiopulmonary function. Spinal fusion surgery has been moderately successful to 
improve respiratory function and posture (McDonald et al. 1995, Yamashita et al. 2001). 
Advances in interventional respiratory support have been particularly effective in 
prolonging life. Even with these advances, failure of the respiratory pump continues to 
be the leading cause of death in DMD (Eagle et al. 2002). However, Importantly 
improvement in respiratory support has uncovered additional challenges in caring for 
patients in a more advanced state of body-wide disease. In particular, the more slowly 
progressing cardiac pathology has emerged as the next most common cause of 
mortality (Eagle et al. 2007). 
 
Although research continues into downstream pathology, promising advances 
have been made in targeting the absence of dystrophin directly. These include viral 
vector-based approaches to introduce a recombanant replacement gene (Sakamoto et 
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al. 2002, Gregorevic et al. 2004, Gregorevic et al. 2006, Schultz, Chamberlain 2008), 
inducing the upregulation of a compensatory gene (Miura, Jasmin 2006), and by 
correcting certain types of dystrophin mutation through exon-skipping (Goyenvalle et al. 
2004) or stop-codon read through (Welch et al. 2007). Cell based therapies – the 
transplantation of homologous, viral vector-corrected, or heterologous, dystrophin-
expressing muscle progenitor cells – are also being investigated (Bachrach et al. 2004, 
Li et al. 2005, Sampaolesi et al. 2006). Of theses, only stop codon readthrough has 
proceeded as far as clinical trial, in which efficacy was minimal (Malik et al. 2010).  
A particularly promising approach is gene replacement by body-wide adeno-
associated virus (AAV) delivery. The size of dystrophin’s cDNA is well beyond the 
carrying capacity of AAV. However, several groups have experimented with truncated 
genes that remove a number of the interior spectrin-like repeats, creating a ‘mini’ or 
‘micro’ dystrophin gene (Wang, Li & Xiao 2000, Harper et al. 2002, Gregorevic, 
Blankinship & Chamberlain 2004). In theory, this serves to replace the DMD state with a 
Becker muscular dystrophy-like disease. A major hurdle for this approach, has been to 
circumvent the response of the host immune system (Wang et al. 2007, Yuasa et al. 
2007). Both the AAV viral capsid, and the expressed transgene have the potential to 
trigger an immune response against muscle cells that take up the AAV vector (Mingozzi 
et al. 2007, Ferrer, Wells & Wells 2000). A novel approach to avoiding the latter case 
has been to use the dystrophin paralog utrophin in place of dystrophin in AAV (Odom et 
al. 2008).  
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Disease models and the Golden Retriever Muscular Dystrophy (GRMD) dog. 
 
A great deal of work has been dedicated to the establishment and 
characterization of animal models of DMD. At the present time several models, both 
vertebrate and invertebrate, are in widespread use. For a list of important models and 
references, see table 1. In general these models have in common a near or complete 
deficiency of a homologous functioning full-length dystrophin protein, and contribute to 
our understanding of dystrophin function, DMD pathology and potential therapeutic 
interventions according to their particular attributes.  
Although evolutionarily distant in relation to humans, the models in the nematode 
worm C. elegans (Bessou et al. 1998), fruit fly D. melanogaster (Neuman et al. 2001, 
Shcherbata et al. 2007), and zebra fish D. rerio (Chambers et al. 2001, Bassett et al. 
2003) have allowed for the application of high-throughput methods. The mdx mouse 
(Bulfield et al. 1984, Sicinski et al. 1989) is the most widely used model of DMD and has 
been crucial to the current understanding of how dystrophin functions in the cell, and to 
much of the work that underpins potential therapies. However, for several reasons 
including compensatory upregulation of utrophin, disease in mdx is far less severe than 
DMD, making it a poor model for the clinical manifestation of the disease in man and 
limiting its usefulness as a pre-clinical model for therapeutic safety and efficacy. 
Coupling of the mdx mutation to targeted mutations in a variety of other genes 
accelerates or attenuates disease progression in the mouse (Grady et al. 1997, 
Deconinck et al. 1997, Wagner et al. 2002, Megeney et al. 1999, Sacco et al. 2010). 
Several studies have shown long-term expression of recombanant truncated dystrophin 
or utrophin and amelioration of the mdx phenotype in the mouse (Sakamoto et al. 2002, 
Gregorevic et al. 2004, Wang, Li & Xiao 2000), but direct translation to the clinic of 
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therapies shown to be efficacious in the mouse is considered unlikely without an 
intermediate step in a model more closely resembling the human disease.  
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Model  Description Moecular deficiency Phenotype References 
Caenorhab-
ditis elegans 
dys-1 
mutant 
Nematode worm Dystrophin null. EMS-
induced 13kb deletion in 
dystrophin ortholog dys-1 
Hyperactivity, 
hypercontraction, 
hypersensitivity to 
acetylcholine. 
Bessou et al, 
1998 
Drosophila 
Melano-
gaster Dys 
mutants 
Fruit fly Dystrophin null. Multiple 
deletion mutants in the 
dystrophin ortholog Dys 
locus 
Decreased mobility, age-
related muscle degeneration, 
neuronal problems. 
Neuman et 
al, 2001, 
Shcherbata 
et al, 2007 
Danio rerio 
sapje 
mutant 
Zebra fish Dystrophin null. Point 
mutation in exon 4 
ortologous dystrophin gene 
leading to a premature stop 
codon. 
Progressive degeneration of 
muscle due to failure of 
myocytes at the myotendonous 
junction. 
Chambers et 
al, 2001, 
Basset et al, 
2003 
mdx Mouse- mdx is the most widely 
studied model of DMD. 
Dystrophin null. 
Spontaneous point mutation 
in orthologous dystrophin 
gene leading to a premature 
stop codon. 
Mild DMD-like phenotype, 
muscle degeneration, centrally 
nucleated fibers, decreased 
activity. Normal life span.  
Bulfeild et al, 
1984, Sicinski 
et al, 1989 
Feline 
Hypertrophic 
Muscular 
Dystrophy 
(FHMD) 
Cat Dystrophin null due to 
spontaneous non-deletion 
mutation in the dystrophin 
gene. 
Severe muscle hypertrophy.  
Cardiomyopathy. 
Gaschen et 
al, 1992, 
Carpenter et 
al, 1989  
Golden 
Retriever 
Muscular 
Dystrophy 
(GRMD) 
Dog- Although this mutation 
spontaneously arose in a golden 
retriever, it has been bred onto a 
beagle background, and referred to 
as canine X-linked muscular 
dystrophy (CXMD) 
Dystrophin null due to a 
spontaneous point mutation 
in a splice-acceptor site at 
exon 7. 
Severe DMD-like phenotype.  Kornegay et 
al, 1988, 
Sharp et al, 
1992 
German 
Short-hair 
Pointer 
Muscular 
Dystrophy 
(GSHPMD) 
Dog- Deletions are more common 
in the DMD population than point 
mutations. The GSHPMD model 
affords the study of phenotypic 
dependence on type of mutation, 
as well as immune tolerance to 
gene-based therapies.  
Dystrophin null due to a 
spontaneous contiguous 
deletion of the entire 
dystrophin locus. Break 
points have not yet been 
defined. 
Similar to GRMD Schatzberg et 
al, 1999 
dko Mouse- The relative preservation of 
mdx myocytes is thought to be due 
in part to the compensatory action 
of a paralogous gene utrophin. Dko  
stands for double knockout and is 
deficient in both proteins.  
Dystrophin and utrophin 
null. mdx crossed with utrn-
/- 
Severe DMD-like phenotype, 
reduced life span. 
Grady et al, 
1997, 
Deconinck et 
al, 1997 
Mstn-/-/mdx Mouse- Myostatin is a negative 
regulator of skeletal muscle mass.  
Dystrophin and myostatin 
null. mdx crossed with 
Mstn-/- 
mdx phenotype is attenuated.  
Increased muscle mass, 
reduced diaphragmatic fibrosis 
and fatty deposition. 
Wagner et al, 
2002 
mdx/MyoD-
/- 
Mouse- MyoD is a transcription 
factor important in msucle 
regeneration. mdx/MyoD-/- is 
deficient in dystrophin and MyoD 
Dystrophin and MyoD null. 
mdx crossed with MyoD-/- 
Severe DMD-like phenotype, 
cardiomyopathy. 
Megeney et 
al, 1999 
mdx/mTR Mouse- mice deficient in mTR, the 
rna component of telomerase, have 
a reduced pool of muscle stem 
cells and reduced muscle 
regenerative capacity.  
Dystrophin and telomerase 
activity null. mdx crossed 
with mTR 
Severe DMD-like phenotype, 
hypotrophy, reduced lifespan. 
Sacco, et al, 
2010 
 
Table 1.  List of important animal models for DMD and their attributes. 
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An important advance in bringing potential therapies to the bedside was the 
discovery and description of several spontaneously occurring dystrophinopathies in 
dogs. Although mutations have arisen in several breeds (Cooper et al. 1988b, Kornegay 
et al. 1988, Schatzberg et al. 1999, Jones et al. 2004, Baltzer et al. 2007, Walmsley et 
al. 2010, Smith et al. 2011), careful preservation and characterization of one in particular 
- the Golden Retriever Muscular Dystrophy (GRMD) model - has proved an essential 
step in pre-clincial evaluation of therapeutic safety an efficacy (Fig.2) (Kornegay et al. 
1988, Sharp et al. 1992, Cooper et al. 1988a, Kornegay et al. 2012). The Golden 
Retriever Muscular Dystrophy model, or GRMD, has a naturally occurring point mutation 
in a splice acceptor site at exon 7 that prevents the successful translation of a full-length 
dystrophin protein (Sharp et al. 1992) and possesses qualities that make it particularly 
valuable for preclinical evaluation of DMD therapeutics. The GRMD reproduces many of 
the major functional and cellular hallmarks of the human disease, on an accelerated 
timescale.  These include widespread muscle wasting and fibrosis, as well as respiratory 
and cardiac functional decline. (Sicinski et al. 1989, Kornegay et al. 2012). A one-year-
Figure 2. An eight month old GRMD dog wearing a jacketed telemetry system for monitoring 
cardiac and respiratory parameters. 
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old GRMD dog is in many aspects as sick as the average ten-year-old Duchenne 
patient. Inherent to the GRMD dog model are several limitations. Housing, care and 
breeding are expensive, and disease presentation is more widely variable than the mdx 
mouse. However, these drawbacks are overshadowed by the GRMD’s close 
pathological resemblance to DMD, and its size. Furthermore, advances have been made 
in applying gene-therapy techniques developed in mdx to the GRMD, though issues of 
delivery and immune response remain (Wang et al. 2007, Yuasa et al. 2007, Yue et al. 
2008, Wang et al. 2010).  
A fact that both complicates our understanding of the disease and provides an 
opportunity for increasing our knowledge of dystrophin’s functions (and of muscle 
physiology in general) is that different muscles within an individual dog are affected to 
differing degrees, and in different ways (Kornegay et al. 1988, Valentine et al. 1990, 
Childers et al. 2001, Nguyen et al. 2002, Cozzi et al. 2001, Kornegay et al. 2003). This is 
not surprising given the wide range of applications the highly conserved contractile 
machinery has adapted to serve within a single organism, be it canine or human. Each 
of the human body’s roughly 640 muscles is integrated into its own control network and 
experiences a different pattern of use, speed of shortening, and force production. 
Although every DMD muscle has the same protein deficiency, the inherent variety in 
muscle size, shape and function, as well as unknown factors, results in the wide range of 
pathological states we see within a single organism. In turn, this variability in the 
pathology of individual muscles plays out in how the organ systems they serve become 
dysfunctional.  
 In the GRMD, we have a unique opportunity to study how muscle-driven 
systems become dysfunctional with manifestations that are directly relevant to clinical 
observations in DMD. The work presented in this thesis lies between the interdependent 
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features of clinical disease progression on the one hand, and the dysfunction of 
individual cells on the other. I concentrated my efforts on the two such systems that are 
critical for sustaining life, and whose failure results in almost all the mortality associated 
with the disease: the respiratory pump, and the heart.  
 
Reserve capacity. 
 
A key concept in this work is reserve capacity, referred to here sometimes simply as 
reserve. As a tissue, muscle is unique in routinely operating over a wide range of 
metabolic rates. It is responsible for the overwhelming majority of the metabolic plasticity 
in an organism as a whole. An example of this plasticity is shown in figure 3. Unlike in 
mammals, muscle fiber types in fish are geometrically segregated, providing a striking 
Figure 3. Photograph of a salmon steak showing geometrical distribution of two types 
of muscle used for different purposes.  “Slow twitch” muscle is outlined in blue on one 
side.  This muscle is used for normal swimming.  The much more voluminous, bright 
orange/red “fast twitch” muscle is only employed briefly for predation or escape.    
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illustration of reserve capacity. The bright red-orange muscle, which takes up the vast 
majority of the volume of the fish, is only active during brief periods of escape or 
predation and is inactive otherwise (Rome, Loughna & Goldspink 1984). For normal 
swimming, fish rely on a much smaller volume of high-endurance muscle, here outlined 
in blue.  
In mammals, the difference in metabolic rate at rest and during maximal 
sustained exercise is on the order of factor of 10, as measured by oxygen consumption 
(Suarez, Darveau & Childress 2004). Elite athletes are capable of far greater ranges. For 
short bursts we can sustain much higher rates of muscle-driven ATP hydrolysis. Two 
major systems in place to provide exchange of metabolites necessary to sustain such a 
range of activities, the heart and respiratory pump, are also muscle-driven and operate 
over a similar range of outputs. Reserve, as it is used for the purposes of this work, is a 
general term to describe the capacity of these systems to operate above and beyond 
what is required to sustain a basal, or resting, metabolic state. Many diseases we 
currently grapple with involve a loss of both respiratory and cardiac reserve. In heart 
disease, diabetes, and chronic respiratory diseases, to name a few, loss of reserve is 
progressive and pernicious, since it is only noticed when metabolic rate is raised by 
climbing stairs or jogging to catch a bus.  
In DMD, the heart and respiratory pump progressively lose function. They lose 
reserve capacity first, and ultimately are not able to provide for even the minimal 
requirements of resting metabolic rate (Fig. 4). This crossover point represents the onset 
of insufficiency, and is not compatible with life without some form of physiological 
compensation. In the typical DMD patient, the respiratory pump reaches this point first, 
after which life is only sustained by permanent mechanical ventilatory support. Advances 
in our ability to provide this support has increased life expectancy in the disease, but 
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have also uncovered the inevitable onset of cardiac insufficiency as a second leading 
cause of death (Eagle et al. 2002). 
Although the clinical consequences of the progressive loss of cardiac and 
respiratory reserve are well known, several obstacles have stood in the way of 
understanding precisely how these pumps fail. First, the systemic nature of the disease 
makes measuring the parameters of reserve directly nearly impossible. Since the 
primary tissue responsible for raising metabolic rate – locomotive muscle – is severely 
affected, DMD patients are incapable of increasing the load on the cardiopulmonary 
system through exercise. Second, to varying extents, the different muscle driven 
systems are dependent on one another. This is particularly true of the heart and 
respiratory pump. In this thesis I address both of these issues in the GRMD dog by 
isolating each system from the confounding influence of its usual in vivo setting, and 
simulate increased metabolic demand through the use of pharmacological agents.  
 
 
 
 
Figure 4. A schematic representation of progressive reserve loss in DMD   
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Respiratory reserve and mechanics in the GRMD dog.  
 
In Chapter 1 I focus on the mechanics of breathing. In healthy humans the vast surface 
area of the lungs is constantly provided with fresh air by the coordinated efforts of 
muscles of the respiratory pump. The progressive dysfunction of these muscles, and not 
the lungs themselves, cause the loss of respiratory reserve seen in DMD. A great deal of 
effort has been dedicated to understanding the decline of the respiratory musculature, 
and how it contributes to the decline of respiratory reserve in DMD, but these studies 
have been limited by the inherent investigational risk to the patient serving as research 
subject (Birnkrant et al. 2010, Finder et al. 2004). Respiration in dogs and humans is 
very similar, and the dog has long been a model for human respiratory mechanics.  
 In the GRMD dog we have a unique and largely untapped resource for 
measuring the changes in respiratory mechanics caused by the absence of dystrophin. 
By directly stimulating the respiratory drive centers using doxapram, and measuring 
pressures, volumes and flows, this study shows that the respiratory pump in the GRMD 
does not simply weaken, but instead undergoes a dramatic remodeling process that is 
potentially protective, and allows for compensatory breathing strategies.  
 
Cardiac reserve in the GRMD dog. 
 
In Chapter 2 I address the body’s other major pump: the heart. Cardiac muscle also 
expresses dystrophin, and becomes progressively dysfunctional in the protein’s absence 
(de kermadec 1994 chenard 1993). However, it is not well understood how the heart – 
though in some ways it is the body’s hardest working muscle – is relatively protected 
from the pathogenic processes at play in skeletal muscle. Most functional studies of 
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dystrophin-deficient hearts have been performed in vivo, or on isolated individual cardiac 
myocytes, but both approaches have drawbacks that complicate the interpretation of 
results. The former is limited by the confounding influence of integration with other organ 
systems, especially in the setting of systemic pathology, and the latter involves a 
process that destroys most of the extracellular matrix – an essential substrate to which 
dystrophin is indirectly linked in vivo. In the studies presented here, I address both these 
issues for the first time by studying the whole, intact heart in isolation. This allowed me 
to address a central question about the dysfunctional myocardium: does the progressive 
loss of cardiac reserve primarily stem from loss of individual cardiac myocytes in an 
manner analogous to what is seen in skeletal muscle, or by dysfunction in cells that 
remain viable? 
 
A high-force myosin isoform and a severe pathology. 
 
In chapter 3 I describe ongoing research into a fascinating element of the disease in the 
GRMD dog that is not shared by humans, but has the potential to answer questions 
about dystrophin’s role in protecting the sarcolemma from the forces generated by the 
contractile apparatus. A major piece of supporting evidence for this role is the single 
muscle fiber-type that appears to be spared from damage in DMD. Muscle fibers of the 
extraocular muscles, those that control the orientation of the eye, express the MYH13 
myosin heavy chain isoform, which due to its unique kinetics, develops far lower specific 
forces than any isoforms expressed throughout the rest of the body (Khurana et al. 
1995). In the GRMD, we observed the converse of extraocular muscle sparing in the 
early and severe pathology of the powerful muscles responsible for closing the jaw. 
These muscles are unique in that they express the myosin heavy chain isoform capable 
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of uniquely high specific force generation: MYH16 (Toniolo et al. 2008, Desjardins et al. 
2002). Jaw muscles in humans are not preferentially affected in DMD, but due to a 
mutation in the gene that is unique to human lineage, they also do not express MYH16. 
In this chapter, I describe approaches to testing the hypothesis that muscle fibers 
expressing MYH16 are inherently more susceptible than their MYH16(-) counterparts to 
contraction-induced damage in the absence of dystrophin. 
 
Clinical biomarkers of disease in GRMD. 
 
In addition to providing insight into organ-system level pathology in DMD, these studies 
serve to advance the usefulness of the GRMD dog as a model for the testing of 
therapeutics. Essential to the effectiveness of the model is our ability to detect and 
quantify incremental improvements in function. In other diseases this is not such a 
problem. For example, efficacy of a treatment for hemophilia A or B can be assessed by 
relatively simple blood tests. But in a disease as complex as DMD, reliable quantitative 
biomarkers are hard to come by.  
Although even an untrained observer might have little difficulty ranking a group of 
GRMD dogs by disease severity, quantification has proved extremely difficult. A dog at 
one extreme may be so sick by 8 months of age as to require euthanasia, while his 
brother or sister might live in relative good health for years. Necessarily small sample 
sizes compound the problem. The development of methods to quantify therapeutic 
efficacy and safety in the face of these challenges is of primary importance to the field. 
Of particular interest are measures that can be taken at multiple time points throughout 
the life of a single animal.  The histological progression of disease in the GRMD has 
been well characterized (Kornegay et al. 1988, Valentine et al. 1990, Childers et al. 
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2001, Nguyen et al. 2002, Cozzi et al. 2001, Kornegay et al. 2003). But though biopsies 
of muscle tissue can provide histological information, they are not direct measurements 
of functional status have the potential to further impact functional decline.  
Current non-invasive measures that can be performed at multiple time points 
range from the more subjective, such as the composite clinical score – where a number 
of clinical markers are assigned a number by the clinician according to severity 
(Sampoleisi et al. 2006, Thibauld et al. 2007, Rouger et al. 2011) – to more objective 
measurements of function. Of the latter, the most well established involves direct 
measurement of distal hind-limb strength by percutaneous electrical stimulation of the 
peroneal and tibial nerves in anesthetized dogs (Kornegay, et al 1994a,b, Childers et al. 
2002, Tegeler et al. 2010, Childers et al. 2011). This approach provides direct functional 
information about certain muscles, but has the limitation of being variable, since minute 
inconsistencies in the placement of the stimulating electrodes can manifest in large 
changes in force. Other quantifiable biomarkers include the following: Tibiotarsal joint 
angles have been shown to correlate with age and other measures of disease severity 
(Kornegay et al. 1994a,b). Accelerometry has been used to quantify changes in gait that 
develop in GRMD dogs as locomotory muscles become weak and fibrotic (Barthelemy et 
al. 2009, Barthelemy, et al. 2011, Marsh et al. 2010).  Magnetic resonance imaging 
(MRI) has been used as an alternative to invasive biopsy for evaluation of the size and 
pathological state of particular muscles (Thibault et al. 2007, Kobayashi et al. 2009, 
Yokota et al. 2009).  Several studies of respiratory and cardiac function have also been 
made and are further discussed in chapters 1 and 2. 
For ethical, as well as scientific reasons, the establishment of additional 
quantifiable markers of disease progression in the GRMD dog is a top priority of the field 
and was the initial motivation for the studies described in this thesis. Since the 
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respiratory and cardiac pumps are muscle-driven systems crucial for maintaining life, 
and their failure in DMD together account for nearly all mortality in the disease, there is 
particular value in studying ways to assess their function directly in response to 
therapeutic intervention. These studies represent the further steps towards establishing 
respiratory and cardiac parameters that can be measured at multiple time points 
throughout the life of an individual animal that reliably represent cardiopulmonary 
reserve capacity. 
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Chapter 1: Doxapram uncovers loss of reserve and adaptive 
remodeling in the respiratory system of the dystrophin-null dog. 
 
Abstract 
 
The clinical course of respiratory decline in Duchenne muscular dystrophy (DMD) is well 
known, but an understanding of the underlying mechanism has been hindered by the 
systemic nature of the disease, and by issues of patient risk. The golden retriever 
muscular dystrophy (GRMD) dog is an important model of DMD that exhibits the major 
functional and cellular hallmarks of the human disease. We report changes to respiratory 
patterns in the GRMD dog at rest analogous to those found in the human disease. 
Furthermore, using doxapram to increase respiratory drive in isolation from overall 
metabolic rate, we report severely reduced reserve, and develop a model of how the 
mechanics of the thoracic cage are altered in the dog. Central to these findings is the 
extreme morphologic remodeling of the dystrophic diaphragm. This muscle was 
profoundly fibrotic, hypertrophic, and reduced in length by deletion of sarcomeres in 
series, resulting in a stiffened muscle with a foreshortened range-of-motion. This 
remodeling allowed the GRMD dog to employ the muscles of the abdominal wall to store 
elastic energy in the diaphragm during expiration to support inspiration, suggesting an 
adaptive process. Our results uncover a more complex picture than has been previously 
drawn of the decline of a muscle-driven system crucial for life. In addition to providing 
much needed endpoint measures for assessing the efficacy of therapeutics, we expect 
these findings to be a starting point for a more precise understanding of respiratory 
failure in DMD. 
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Glossary of terms and abbreviations. 
 
Tidal Volume (Vt) – The volume of air inspired in a single breath, also defined as 
the difference between end-inspiratory volume and end-expiratory volume 
 
Respiratory Rate (RR) – Breathing frequency expressed as breaths per minute. 
 
Rate of Ventilation/Ventilatory Rate – The volume of air exchanged per unit time. 
Here, rate of ventilation is corrected for body weight, and expressed as milliliters 
per kilogram per minute. Rate of ventilation is also equal to the product of tidal 
volume and respiratory rate. 
 
Vab and Vrc – Rib cage and abdomen volume. In the two-compartment model of 
respiration, inspiration is accompanied by expansion of the rib cage and 
abdomen. The distribution of tidal volume between these two compartments 
depends on the coordinated actions of the various inspiratory and expiratory 
muscles.  
Pgas – Gastric pressure. 
Pes – Esophageal pressure. 
Pdi – Trans-diaphragmatic pressure. Defined as Pgas - Pes 
Respiratory Inductance Plethysmography (RIP) – A technique using inductance 
coils to measure changes in the cross-sectional areas of the rib cage and 
abdomen during respiration for the purposes of approximating tidal volume and 
the relative contributions of Vab and Vrc. 
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Introduction. 
 
Duchenne muscular dystrophy (DMD) is a recessive X-linked disease of muscle caused 
by mutations in the dystrophin gene (Hoffman, Brown & Kunkel 1987). Failure of the 
respiratory system is the major cause of death in DMD. Patients experience a 
progressive loss of respiratory reserve capacity that culminates in insufficiency and 
dependence on external support (Birnkrant et al. 2010). A major obstacle has stood in 
the way of understanding the mechanisms that connect the cellular pathology to 
systemic respiratory failure. Because the disease affects the major organ responsible for 
increasing metabolic rate – locomotory muscle – patients are unable to use exercise to 
increase their demand for ventilation. Therefore efforts to measure loss of reserve 
capacity have been necessarily indirect: limited to volitional tests of maximal pressures 
and volumes, and studies of respiratory mechanics to breathing at rest. (Birnkrant et al. 
2010, Gayraud et al. 2010, Nicot et al. 2006, Finder et al. 2004). However, it is clear 
even from these studies that respiratory dysfunction in DMD is more complex than a 
general weakening of respiratory muscles. For instance, patients show a progressive 
loss of the abdominal component of tidal volume indicating a loss of diaphragm range-of-
motion (Lo Mauro et al. 2010, Romei et al. 2012). But what is not known is what causes 
this loss, and how it affects respiration under increased metabolic load.  
Unlike the dominant model of DMD, the mdx mouse, the GRMD dog exhibits 
advanced body-wide functional and cellular pathology within the first year of life 
(Kornegay et al. 1988, Kornegay et al. 2012). For this reason, and because of its size, 
the GRMD is currently the most important model for pre-clinical evaluation of therapeutic 
intervention in DMD. Two groups have addressed the question of respiratory function in 
the dystrophin null dog. Brumitt et al noted a marked thickening and undulatory 
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appearance of the GRMD muscular diaphragm by radiographic and ultrasound studies. 
In a study of Canine X-linked Muscular Dystrophy (CXMD) dogs, which have the GRMD 
mutation bred on to a beagle background, Yuasa et al noted fibrosis and fast-to-slow 
fiber type shifts to be more severe in the diaphragm than in other body muscles. These 
observations suggest that the ventilatory pump is severely affected in the GRMD. 
(Brumitt et al. 2006, Yuasa et al. 2008) However, the extraordinary potential of the 
GRMD as a model of respiratory mechanics and loss of reserve in DMD has not been 
exploited. Volitional measures of pulmonary function are inapplicable and, as in DMD, 
the dogs are exercise-averse due to severe systemic disease. Therefore, we used a 
novel pharmacological approach to increase respiratory drive independent of overall 
metabolic rate. 
The respiratory stimulant doxapram hyrdrochloride is thought to act on the TASK 
family of carotid body channels and to affect drive in a manner independent of alveolar 
anesthetic concentration (Cotten et al. 2006). Here we used doxapram in GRMD and 
normal control animals under inhalational anesthesia, while monitoring volumes and 
pressures, to uncover respiratory dysfunction. These studies were coupled with 
histological analysis of respiratory muscles. Our aims in this study were twofold: to 
explore a model for human respiratory pump failure utilizing more invasive measures 
than are possible in DMD, and to identify potential biomarkers for the efficacy of 
therapeutics that could be safely assessed at multiple time points throughout the life of 
an animal. 
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Brief Methods (for a detailed description see appendix: methods) 
 
In the present study we used dynamic measurements of volume and pressure at rest 
and under load in GRMD and normal control dogs to make inferences about the 
progressive dysfunction of individual respiratory muscle groups and their contribution to 
loss of respiratory reserve. These functional studies were supplemented with histological 
examinations of respiratory muscles from a subset of dogs at the time of euthanasia.  
Volume distribution and timing in awake dogs at rest. 22 GRMD and 15 normal control 
dogs were studied using respiratory inductance plethysmography (RIP) during periods of 
conscious, restful breathing. This technique allows for independent measurements of 
changes in the volume of the rib cage (RC) and abdominal (AB) compartments during 
breathing. Vests fitted with RIP bands were fitted and dogs were placed in lateral 
recumbency. One-minute periods of calm regular breaths were selected from RIP 
tracings and analyzed using Vivologic software.  
Volume and pressure measurements in anesthetized dogs. A second set of dogs (7 
GRMD, 5 normal control) were studied during a period of inhalational anesthesia. In 
addition to RIP, dogs were instrumented with gastric and esophageal pressure 
transducers. Tidal volume and respiratory rate were also continuously measured using 
an Omida Excell 210 anesthesia machine and recorded with a video camera. After 
instrumentation and several minutes of baseline data collection, dogs were given an 
initial bolus dose of doxapram hydrochloride (1mg/kg) followed by a second dose of 
2mg/kg five minutes later. 
24 
 
Histology. Respiratory muscles from 7 GRMD and 5 normal control dogs were excised at 
time of euthanasia and processed to determine gross dimensions, sarcomere length and 
collagen content. 
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g892 - 10 16.6 17.5 246.5 3.5 12.1 5 25 
g092 - 13 13 142 375.3 10.9 22.1 13 17 
g124 - 6 9.8 58.2 189.8 5.8 9.7 10 20 
g547 - 17 17.3 57.5 372.3 8.2 18.6 7 23 
g033 - 16 19.3 116.5 408 9 17.3 13 25 
g566 - 16 13.8 38.8 333.8 7.8 19.6 5 17 
g890 - 17 20 90.8 308.1 5.7 10.6 16 29 
    
        
n290 + 7 21.5 109.8 304.4 11 23.3 10 16 
n559 + 7 20.3 83.1 463.3 13.8 31.3 6 15 
n530 + 9 23 82.8 346.4 10.3 22.6 8 16 
n256 + 13 27.8 135.1 330.9 11.3 21.6 12 19 
n016 + 7 20 115 576.3 10.5 24 10 25 
  
Results. 
  
Diaphragm contribution during restful breathing. Asymmetrical weakness of individual 
respiratory muscle groups often manifests as changes in the relative motion of the rib 
cage and abdominal compartments, and is measureable by RIP (Cohen et al. 1982). In 
the time domain, diaphragm weakness takes the form of thoraco-abdominal asynchrony 
Table 2.  Major ventilatory parameters of seven GRMD and five normal control dogs 
included in the doxapram study.  
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(TAA), where the descent of the diaphragm and consequent expansion of the abdomen 
lags behind rib cage expansion during inspiration (Gilbert et al. 1974). In the extreme 
case of TAA, called abdominal respiratory paradox, the abdomen moves 180˚ out of 
phase with the rib cage (Cohen et al. 1982). Although TAA has been reported in 
advanced DMD, a more common presentation of diaphragmatic dysfunction is the 
progressive loss of the abdominal component of tidal volume (∆Vab), which indicates a 
reduction of the diaphragm’s range of motion (Lo Mauro et al. 2010, Romei et al. 2012).  
Figure 5. RIP studies in awake, laterally recumbent dogs during a period of quiet 
breathing at rest.  Abdominal component of inspired volume (∆Vab) expressed as a 
percentage of tidal volume (Vt).  a) ∆Vab of 22 GRMD (closed circles) and 17 normal 
control (open circles) dogs by age.   b) Decline of ∆Vab in 7 individual GRMD dogs. 
Both time points for each dog in b are reproduced in a. 
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To determine the contribution of the diaphragm to tidal volume, we used RIP in 22 
GRMD and 15 normal control, laterally recumbent dogs during periods of wakeful, quiet 
breathing. Dogs ranged in age from 4 to 18 months. We observed no significant 
difference in the relative timing of rib cage and abdominal motion between the two 
groups as measured by respiratory phase angle. However, GRMD dogs as a whole 
showed reduced ∆Vab, expressed as a percentage of Vt, compared to normal controls 
(20.2% ±15.8 vs. 54.2% ±16.3). The difference was larger in older dogs (Fig. 5a). Seven 
GRMD dogs from this group were studied at multiple time points, and all showed an age 
related decline in ∆Vab (Fig.5b).  
GRMD dogs lose volumetric respiratory reserve. Data from individual animals is 
summarized in table 2. To measure how altered respiratory mechanics at rest affected 
respiratory reserve, we used low doses of the respiratory stimulant doxapram in a 
second set of 7 GRMD and 5 normal control dogs. In anesthetized laterally recumbent 
dogs, an intravenous bolus of doxapram was administered to temporarily stimulate an 
Figure 6. Effect of doxapram on rates and volumes. Ventilatory parameters in 7 GRMD 
and 5 normal control dogs given IV bolus doxapram while under inhalational 
anesthesia and laterally recumbent. a) Max ventilatory rates after 1 and 2mg/kg 
doxapram bolus. b) Max tidal volume achieved after doxapram bolus (1mg/kg). c) Max 
respiratory rate. d) ∆Vab before and at max ventilation after doxapram bolus (1mg/kg). 
* = p<0.01 
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increase in respiratory drive. Doxapram resulted in a transient increase in overall rate of 
ventilation that peaked around 60 seconds after administration and fell to near-baseline 
by 5 minutes. Doxapram (1mg/kg) revealed severe tidal volume (Vt) limitations in the 
GRMD dogs. GRMD dogs reached lower weight-specific Vt than normal control dogs 
(15.72 ± 4.77 vs. 24.55 ± 3.86 ml/kg) to achieve similar peak weight-specific rates of 
ventilation, with the difference being made up by slightly higher respiratory rates. After a 
subsequent bolus of 2mg/kg, GRMD dogs exhibited no significant further increase in 
ventilation, whereas normal control dogs did. Collectively these data suggest that 
respiratory reserve in the GRMD is largely limited to their ability to increase respiratory 
rate (Figs. 6,7).  
 
Increased ventilation does not elicit signs of diaphragm weakness in the GRMD. We 
were interested in whether the demands made on the diaphragm by increased drive 
would uncover TAA not present at rest. Anesthesia alone had no effect on TAA or ∆Vab 
in GRMD or normal dogs prior to doxapram bolus, and neither parameter changed in 
either group in response to the drug. The ratio of change in abdominal pressure (∆Pgas) 
Figure 7. Ventilation-tidal volume relationships after doxapram bolus (1mg/kg) in 7 
GRMD (red) and 5 normal control (blue).  Points along curves at 10 second intervals 
after bolus. 
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to change in trans-diaphragmatic pressure (∆Pdi) during inspiration can also be used to 
diagnose paradoxical diaphragm motion. A ∆Pgas /∆Pdi of less than zero is indicative of 
upward diaphragm motion during inspiration. We observed no difference between the 
two groups using this method as well (Fig. 8).  
 
GRMD dogs increase Vt primarily by actively driving lowered end-expiratory volume. We 
were interested in whether reduced volumetric reserve would be accompanied by 
abnormal end-inspiratory and end-expiratory volumes (Vei, Vee), which would indicate 
altered breathing strategies. Figure 9 shows maximum Vei and minimum Vee by 
compartment before and after doxapram bolus (1mg/kg). The small increases in Vt that 
the GRMD dogs were able to achieve were almost entirely the result of lowered Vee. The 
decrease in Vee being primarily in the abdominal compartment suggests the action of the 
expiratory muscles of the abdominal wall, indicative of a loss of vital capacity in the 
GRMD analogous to that seen in the human disease. If the abdominal expiratory 
Figure 8. GRMD dogs show no signs of TAA at rest or in response to doxapram.  
Pressure and volume measures of asynchronous motion of rib cage and abdominal 
compartments. ∆Pgas/∆Pdi during inspiration (left plot) and respiratory phase angle (right 
plot) in GRMD (red circles) and normal control animals (blue circles) before and after 
doxapram bolus.  
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muscles drive chest wall volume below its equilibrium point during expiration, we would 
expect to see a consequent increase in Pgas. GRMD dogs demonstrated a pattern of 
transient increases in Pgas over two timescales after doxapram bolus. The first was 
repeated each breath at end-expiration, seen as a rightward spike in Pes / Pgas loops 
(Fig. 10). The second was a longer-term increase occurring over several breaths during 
peak doxapram effect. This can be seen as a rightward shift of the entire loop. The end-
expiratory Pgas wave only emerged at the higher dose in normal dogs, and then to a 
much lesser degree than in the GRMD, whereas there was no long-term increase in Pgas 
after either dose in normal dogs.  
 
The GRMD diaphragm undergoes gross remodeling accompanied by severe collagen 
deposition. The muscular diaphragm of the GRMD was drastically shortened in the 
direction of contraction compared to normal dogs (31.67 ± 7.23 vs. 75.56 ± 15.57mm). 
The GRMD diaphragm was also thickened (8.06 ± 3.41 vs. 2.44 ± 0.35mm). 
Figure 9. Compartmental volumes (Chest wall (Vcw), rib cage (Vrc), abdomen (Vab)) in 
response to doxapram bolus (1mg/kg) in GRMD and normal control dogs. End-inspiratory 
(solid lines) and end-expiratory (dashed lines) volumes before and at maximum ventilation 
after doxapram bolus in 7 GRMD (red) and 5 normal control (blue) dogs. Baseline end-
expiratory volume is set to zero.  Tidal volume is represented by the difference between end-
inspiratory and end-expiratory chest wall volume. 
 
30 
 
Furthermore, at these dimensions, sarcomere length was not different between the two 
groups, which suggests that an active process of remodeling, rather that hyper-
contraction is involved (Fig. 11). Transverse sections of diaphragm muscle stained for 
collagen showed fibrosis over nearly half of the cross sectional area of GRMD 
diaphragm, indicating that a combination of hypertrophy and fibrosis is responsible for 
the increased thickness in this muscle (Fig. 12). Other major respiratory muscles also 
showed increased fibrosis relative to limb muscle in the GRMD, but the diaphragm was 
the most severely fibrosed.  
Figure 10. Pressures in response to doxapram bolus (1mg/kg) in GRMD and normal control 
dogs. Representative abdominal (Pgas) and Rib cage (Pes) pressure-pressure loops from 
GRMD and normal control dogs before (solid lines) and at maximum ventilation after 
(dashed lines) doxapram bolus.  Arrows indicate loop direction.  Circles indicate end-
expiration. 
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Figure 11. Gross morphology of the GRMD diaphragm.  a) Representative sketches of 
GRMD (red) and normal (blue) whole diaphragms viewed looking cranially. b) Strips of 
muscular costal diaphragm from GRMD and normal dogs viewed in longitudinal cross 
section. c) length-thickness relationships of GRMD (red) and normal (blue) costal 
muscular diaphragm. Inset) Sarcomere lengths at these muscle lengths.  
 
Figure 12. Transverse cross sections of respiratory muscles from  representative GRMD 
and normal dogs stained with picrosirius red.  Collagen is red and muscle cells are gold 
(top). Scale bar (green) = 100µm Quantitaitve analysis of  collagen relative to total 
cross-section area of respiratory muscles from images in multiple dogs (white number in 
bar is sample size).  GRMD in red.  Normal control in blue.  
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Discussion. 
 
This study represents a detailed look at the morphology and kinematics of the 
respiratory pump in the GRMD dog. Stimulation of respiratory drive by the use of 
doxpram allowed us to track quantitative and qualitative changes to respiratory reserve 
and mechanics in the dystrophin-null animals. Central to these changes is an aggressive 
remodeling over time of the muscular diaphragm in the GRMD dog. 
The diaphragm in the GRMD appears to be uniquely effected among muscles in 
the absence of dystrophin. In this way it parallels the aged mdx mouse – there the 
diaphragm is the only muscle in which pathology approaches that seen across all 
muscles in the human disease (Stedman et al. 1991). In the GRMD the dramatic change 
in gross dimensions of the muscle is far more striking than the extreme presentation of 
common pathological markers, such as fibrosis. Although previous studies had 
suggested the diaphragm in the dog are specially affected in the disease, no description 
of the gross morphology, or its effects on respiratory mechanics has been reported 
(Yuasa et al. 2008). This profound remodeling implies that respiratory mechanics would 
be significantly altered in the absence of dystrophin. A primary aim of this study was to 
develop an approach to the serial measurement of these changes and their effect on 
reserve capacity.  
In the awake GRMD dog, this manifested most strongly as a reduction in ∆Vab – 
a measure of the diaphragm’s range of motion, and contribution to tidal volume, a 
phenomenon well documented in DMD (Lo Mauro et al. 2010, Romei et al. 2012). An 
important limitation of this model is that wakeful breathing is necessarily quiet breathing 
due almost entirely to the inability, or unwillingess of the GRMD dog to load the 
respiratory system by increasing metabolic rate once the disease has reached a certain 
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point. This is likely not a function of the respiratory system itself, but rather of the 
advanced pathological state of the major organ responsible for metabolic loading: 
locomotive muscle. In this way, GRMD mimics the human disease in post-ambulatory 
boys. There, respiratory reserve capacity is an essential indicator of overall disease 
state and prognosis, but must be measured indirectly by means of voluntary respiratory 
maneuvers (Gayraud et al. 2010, De Bruin et al. 2001). Although such maneuvers are 
impossible in the dog, we were able to make more direct measurements of reserve 
capacity (and mechanism via chest wall kinematics) with the use of doxapram.  
For nearly forty years the diaphragm has been understood to be the only 
importantly active muscle involved in breathing at rest (Grimby, Goldman & Mead 1976). 
Studies of graded exercise have established the progressive recruitment of the various 
components of the respiratory pump as demand for ventilation increases (Aliverti et al. 
1997). The mechanism of action of Doxapram’s primary site of action in carotid 
chemosensing suggested the possibility that the pattern of motor unit and muscle group 
recruitment would remain intact in the deeply anesthetized dog (Cotten et al. 2006, Yost 
2006). This expectation was entirely born out by our observations. In normal control 
dogs an intravenous bolus of doxapram caused an initial increase in tidal volume 
followed by an increase in respiratory rate, as would be expected from graded exercise.  
Only at the higher doxapram dose of 2mg/kg studied did normal dogs begin to 
recruit abdominal muscles during expiration – seen here as an increase in end-
expiratory Pgas – to aid expiratory flow and reduce end-expiratory volume. The GRMD 
departed from this pattern in several important ways: At the lower doxapram dose, 
GRMD dogs achieved nearly the same rate of ventilation as normal dogs, however they 
did it with significantly smaller increases in tidal volume, making up the difference with 
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increased respiratory rate. Moreover the increases in tidal volume that they did achieve 
relied on selective tapping of expiratory reserve capacity.  
Taken together these data indicate a respiratory pump farther along the trajectory 
of progressive recruitment than their normal counterparts for the same rate of ventilation, 
indicating a loss of reserve. Furthermore, these data suggest that the GRMD respiratory 
pump employs a compensatory strategy, qualitatively different than the healthy pump, 
centered on the dramatically remodeled diaphragm. An early hypothesis that shaped this 
inquiry was that a progressively weakening diaphragm would, as in other pathologic 
states where diaphragm function is negatively affected, present as an increasing degree 
of thoracoabdominal asynchrony (TAA) as negative trans-thoracic pressure developed 
by intercostal and auxiliary inspiratory muscles overcomes the force generating capacity 
of the compromised diaphragm, drawing it cranially during inspiration. However, 
although TAA has been reported in patients with DMD at very advanced stages of the 
disease (Smith, Edwards & Calverley 1989), it is not a predominant component of restful 
breathing despite early and preferential diaphragm dysfunction. Likewise in this study, 
while we observed a consistent decline in ∆Vab in the GRMD, and found the diaphragm 
to be at an advanced state of pathology by a year of age, no significant difference in 
TAA was seen between GRMD and normal dogs at rest or after bolus administration of 
intravenous doxapram.  
TAA resulting from a weak or non-functional flaccid diaphragm is an energetically 
and volumetrically unfavorable scenario for gas exchange (Willis et al. 2004). The most 
dramatic clinical example of TAA is diaphragm paralysis from damage to the phrenic 
nerves. Surgical intervention, termed plication, involves reduction of the area and 
excursion of the non-functional diaphragm, which serves to eliminate TAA, increase 
maximum lung volumes, and reduce the work of breathing for a given tidal volume 
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(Dagan et al. 2006, Takeda et al. 1995, Schwartz, Filler 1978). In other words it is better 
in several ways to have a short stiff diaphragm with little or no range of motion than a 
compliant but weak or non-functioning diaphragm. The remodeling observed in the 
GRMD results in an analogously shortened or “autoplicated” muscular diaphragm. It is 
not a unique example of this phenomenon. Hyperinflation of the lungs in chronic 
obstructive pulmonary disease (COPD) leads to an analogous remodeling: there 
sarcomeres are removed in series in such a way that ideal resting sarcomere length is 
maintained in the shortened muscular diaphragm, thereby allowing Pdi to be more 
effectively generated around a higher chest wall equilibrium volume (Clanton, Levine 
2009, Dodd, Brancatisano & Engel 1984). In addition, remodeling in COPD has been 
shown to augment the recruitment of auxiliary muscle groups to facilitate ventilation. 
Grimby et al first showed in healthy subjects during exercise that contraction of 
abdominal wall muscles during expiration functioned not only to increase expiratory flow, 
but also to store elastic and gravitational energy in the chest wall for the next breath 
(Grimby, Goldman & Mead 1976). The release of this energy upon relaxation of the 
abdominal wall muscles at the initiation of inspiration, termed postexpiratory recoil 
(PER), results in a significant contribution to inspiratory Pdi and flow. Subsequent studies 
have established that PER is a strategy adopted in COPD to compensate for reduced 
diaphragm function (Dodd, Brancatisano & Engel 1984, Levine et al. 1988).  
In the GRMD dog we saw strong indicators of PER in the form of transient 
increases in Pgas at end-expiration, appearing as a rightward spike in the Pgas-Pes loop. 
Superimposed on this pattern, there was a longer-term increase in Pgas lasting for 
multiple breaths during peak doxapram effect; seen as a rightward shift of the entire Pes-
Pgas loop. This longer-term increase in Pgas corresponded with lowered end-inspiratory 
and end-expiratory Vab. At peak rate of ventilation the diaphragm is driven farther into the 
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chest by action of the abdominal wall muscles, and thus moves in a range where its 
intrinsic elastic recoil is higher, thus increasing the PER effect. The combination of this 
action with the increased elastance afforded by fibrosis and hypertrophy potentially 
yields increased Pdi (and flow) during inspiration without a consequent increase in force 
at the level of the sarcomere. Whether similar compensatory changes occur in the 
human diaphragm in the absence of dystrophin is unknown. However, the well-
established decline in ∆Vab associated with DMD, and lack of significant TAA in most 
cases, suggest is likely.  
The observation that GRMD dogs recruit a broader range of respiratory muscles 
than normal control dogs to achieve the same rates of ventilation suggests that the lack 
of a dose-response in this population reflects a functional limitation of the respiratory 
pump. However, we cannot rule out the possibility that the effects of doxapram on the 
CNS are different in a dystrophin-null setting. In addition to muscle cells, dystrophin is 
expressed in neurons, localizing to the cytoplasmic face of the cell membrane together 
with other members of the dystrophin-associated glycoprotein complex (DGC). Although 
the functions of dystrophin and the DGC in the CNS are not well understood, cognative 
impairment has been identified in some DMD patients and progress has been made in 
identifying potential biochemical pathways that might be implicated (Cotton, Voudouris & 
Greenwood 2005, Allen, Rodgin 1960, Waite et al. 2009).  
This study focused on animals in a relatively advanced state of disease. Further 
work is required in younger animals to determine the progression of this phenotype. It is 
important to know at what rate diaphragm remodeling occurs. For example, TAA 
resulting from diaphragm weakness would require the diaphragm to lengthen during 
contraction, a scenario known to cause acute and lasting pathology in the absence of 
dystrophin (Petrof et al. 1993a). Early TAA, (in young dogs with greater metabolic 
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plasticity) is therefore a possible mechanism for the extreme, remodeled morphology of 
the diaphragm at the later stages studied here.  
This interpretation of adaptive diaphragm function depends on increased fibrosis. 
Therefore therapies that target fibrosis without addressing the underlying contractile 
pathology could result in a diaphragm susceptible to TAA and less able to store energy 
developed by the abdominal wall muscles, thus having a deleterious affect on the 
efficiency of the respiratory pump. 
 A better understanding of the progression of this pathology – indicated here in a 
cross section of dogs at a range of ages – is necessary for the refinement of the 
techniques employed here for use as markers of disease progression and of the efficacy 
of therapeutic interventions. Non- or minimally invasive biomarkers are currently limited 
to non-quantitative analyses of gait, and measurements of passive range of motion and 
of proximal and distal hindlimb muscle force during nerve electrostimulation (Kornegay 
et al. 2012). The latter are usually performed under anesthesia at multiple time points 
during the life of an animal. Measures of respiratory function using doxapram at the 
doses used here has the advantage and potential of being a safe, non-invasive 
procedure that can be performed serially under the same anesthetic course as these 
other studies. This technique has the further advantage of being a direct measure of 
function in a muscle-driven system crucial to the lifespan and healthspan of patients with 
DMD. 
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Chapter 2: Loss of Contractile Reserve and Diastolic 
Dysfunction in the Isolated Perfused Dystrophin-null Canine 
Heart 
 
Abstract. 
 
Recent advances in interventional respiratory support have increased the lifespan of 
patients with Duchenne muscular dystrophy (DMD). Heart failure has emerged as a 
significant cause of mortality and morbidity. However, an understanding of the causal 
connection between dystrophin deficiency and the clinical phenotype remain elusive. 
The golden retriever muscular dystrophy (GRMD) dog is an important model of DMD 
that exhibits the major functional and cellular hallmarks of the human disease, including 
heart failure. We report profoundly abnormal systolic and diastolic function in 
Langendorff-perfused intact hearts isolated from GRMD dogs long before the onset of 
clinical signs of heart failure. However, hearts tolerated repeated stretch to preload 
pressures well in excess of that possible in vivo without subsequent loss of developed 
pressure. Hearts exhibited a loss of Frank-Starling response, beta-adrenergic inotropy 
and lusitropy, while chronotropy was less strongly affected. Our modification of the 
isolated, perfused canine heart represents an important endpoint measure of therapeutic 
efficacy and provides a much-needed bridge between studies of disease mechanism at 
the cell and in vivo levels.  
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Glossary of terms and abbreviations. 
 
Heart Rate (HR) – Frequency of cardiac pump cycling expressed as beats per 
minute. 
 
Stroke Volume (SV) – Volume of blood ejected from a ventricle in a single heart 
beat.  
 
Cardiac Output (CO) – Volume of blood pumped by the heart per minute. CO is 
equal to the product of HR and SV. 
 
Compliance – The inverse of stiffness. A left ventricle with reduced compliance 
requires higher filling pressures to achieve a given end-diastolic volume.  
 
Inotropy – Increase in contractility of the heart in response to metabolic demand.  
Lusitropy – Increase in the rate of relaxation in cardiac myocytes  
Chronotropy – Increase in heart rate.  
 
Introduction. 
 
Duchenne muscular dystrophy (DMD) is a recessive, X-linked disease of muscle caused 
by the subclass of mutations in the dystrophin gene that result in deficiency of the 
protein (Hoffman, Brown & Kunkel 1987). Although respiratory insufficiency is the 
dominant cause of mortality and morbidity in the disease, improvement in interventional 
respiratory support has uncovered heart failure as the next leading cause of death83 
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Eagle,M. 2002;Heart disease in DMD usually manifests as arrythmia and ultimate dilated 
cardiomyopathy (de Kermadec et al. 1994, Chenard et al. 1993). Potential therapies that 
target skeletal muscle, without also improving cardiac function, have been shown to 
accelerate heart failure (Eagle et al. 2007, Townsend et al. 2007, Townsend et al. 2008). 
In addition, mutations causing the allelic disorder Becker Muscular Dystrophy in which 
an internally deleted for of dystrophin is expressed often develop cardiomyopathy when 
the skeletal muscle manifestations of the disease are relatively limited (Romfh, McNally 
2010). These considerations focus renewed attention on improving our understanding of 
the mechanism of cardiomyopathy at early stages of DMD/BMD. 
The mechanisms linking the molecular deficiency to the clinical presentation of 
dystrophic heart failure have been elusive. Contractile ‘reserve’ in skeletal muscle exists 
in the form of additional myofibers that can be recruited in an all-or-none fashion as 
needed (Henneman, Somjen & Carpenter 1965). In contrast, contractile plasticity in the 
heart resides entirely within the individual cardiac myocyte as continuously modulated by 
neurohormonal signaling, and every cell contributes to every systole. In DMD loss of 
maximal force production by skeletal muscle is largely due to the loss of individual 
myocytes via the cumulative effects of repetitive sarcolemmal injury (Petrof et al. 1993a). 
The extent to which the clinical loss of cardiac reserve is caused by a process analogous 
to that in skeletal muscle, versus other mechanisms whereby cardiomyocytes remain 
viable but dysfunctional is unknown.  
Approaches to this problem have taken two forms. Isolated cardiomyocytes from 
the mdx mouse and GRMD dog rupture and fail by a process superficially analogous to 
that of skeletal myocytes when exposed to passive stretch (Townsend et al. 2010, 
Yasuda et al. 2005). However in a disease where direct structural linkage of components 
of the dystrophin-associated protein complex to the extracellular matrix is implicated, the 
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enzymatic destruction of extracellular collagen to isolate individual myocytes complicates 
interpretation. At the other extreme, several non-invasive studies have contributed to our 
understanding of the natural history of cardiomyopathy in the GRMD through in vivo 
studies utilizing electrocardiography (Moise et al. 1991, Yugeta et al. 2006), 
radionucliotide angiography (Devaux et al. 1993)., cardiac MRI (Kellman et al. 2009), 
echocardiography (Moise et al. 1991, Yugeta et al. 2006, Chetboul et al. 2004, Chetboul 
et al. 2007, Takano et al. 2011). Dogs ultimately develop dilated cardiomyopathy and 
electrocardiographc defects are present by 6 months of age. However, 2D 
echocardiography using standard indices are usually normal during the first 2 years of 
life (Moise et al. 1991, Yugeta et al. 2006). investigation of cardiac myocyte failure and 
reserve capacity prior to the onset of dilated cardiomyopathy in vivo is complicated by 
the systemic nature of the disease, by physiological restrictions on preload, and by the 
fact that major parameters, such as left ventricular (LV) volume can only be estimated 
indirectly.  
To address these limitations, we studied intact hearts isolated from GRMD dogs 
ranging in age from 6 to 19 months, allowing direct control of LV volume, beta-
adranergic stimulation, and perfusion, while maintaining extracellular matrix integrity. We 
hypothesized that if the primary pathology were due to acute injury to individual 
cardiomyocytes, as suggested by previous studies of isolated myocytes, viable 
myocardium would remain responsive to beta-adrenergic stimulation, but would suffer an 
immediate and profound decrease in developed pressure after being exposed to LV 
preloads well in excess of those seen in vivo. And if not, we wished to identify other 
mechanisms that might be involved in the progressive loss of cardiac reserve seen in 
DMD. To address these issues we had to modify previously described non-working heart 
Langerdorff perfusion systems to enable the use of high LV filling pressures by using a 
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surgically mounted mandrill at the mitral annulus and a left ventricular vent across an 
apical vetriculotomy (Langendorff 1895, Bell, Mocanu & Yellon 2011). 
 
Brief methods (for a complete description, see appendix: methods). 
 
The Langendorff apparatus was designed and built in-house from modified 
components of a clinical heart-lung bypass system. A detailed schematic of the system 
is provided in appendix: methods. The system was made up two main parts: To maintain 
the heart in sinus rhythm we employed a perfusion circuit primed with 1 liter of 
sanguinous perfusate (80% Krebs-Henseleit, 20% blood from dog) consisting of a heat 
exchanger, membrane oxygenator, filter and pump. To measure contractility we used a 
pressure transducer consisting of a fluid-filled balloon attached to a cannula entering the 
left ventricle via the mitral annulus and fixed in place with a purse-string suture. After 
procuring the heart, and mounting it in the Langendorff apparatus, we allowed it to warm 
to 37˚C before defibrillating. Once the heart achieved sinus rhythm, the following 
experimental protocols were followed. 
  We increased left ventricular volume by steps. Step size was 1,2, or 4 ml, and 
was determined by taking into consideration the size of the heart, and whether it came 
from a GRMD or normal control animal. Volume was increased until one of the following 
criteria was met: we reached a volume at which developed force dropped from the 
previous volume, arrhythmias occurred, or preload pressure exceeded 50mmHg.  
After the initial volume ramp, we added epinephrine to the perfusate reservoir 
and stirred to mix. We monitored the LV pressure trace until increases in heart rate and 
developed force reached a plateau. This usually took about 5 minutes depending on the 
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rate of perfusion. We began with a concentration of 10µg/L, and subsequently added 
23µg/L and 67µg/L for calculated final concentrations of 10, 33, and 100µg/L. 
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g054 - 19 17.8 135 7.58 101 39 18 36 75 
g027 - 13 13.6 101 7.43 107 26 19 53 80 
g514 - 16 20.5 138 6.73 130 29 17 31 100 
g087 - 13 14.1 116 8.23 143 36 12 53 55 
g124 - 6 9.8 73 7.45 117 34 11 90 163 
g892 - 10 16.6 128.7 7.75 108 20 22 54 101 
g635 - 18 17.5 120 6.86 84 21 15 39 95 
    
         
n016 + 7 21.5 174 8.09 83 67 24 * * 
n290 + 9 23 196.6 8.55 106 109 33 74 163 
n530 + 7 20 181 9.05 101 86 33 42 194 
n070 + 20 35 282 8.06 102 102 45 51 179 
Table 3.  Major parameters of seven GRMD and four normal control dogs included in the 
langendorff study. The heart from dog “n016” forcefully detached from the mandrel at high rates 
of epinephrine perfusion, data omitted (*). 
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Results. 
 
GRMD LVs tolerate stretch but have blunted compliance. Table 3 shows measured 
parameters in hearts from 7 GRMD and 4 normal canine hearts. Carbon fiber 
instrumented, isolated cardiac myocytes from mdx mice and GRMD dogs undergo 
terminal contracture seconds after being passively stretched to sarcomere lengths of 2 
µm, well within the physiological range (Townsend et al. 2010, Yasuda et al. 2012). To 
test the hypothesis that cardiomyocytes fail in this way in the setting of the intact, 
perfused, beating heart, we increased LV volume in a stepwise manner to preload 
pressures in excess of 30 mm/Hg, a level not possible in vivo without inciting severe 
pulmonary edema. Although we achieved sarcomere lengths of 2.2 µm or greater, we 
saw no acute loss of developed force, and ventricular performance was stable for 
periods well in excess of an hour (Fig. 13) As in isolated cell studies, whole GRMD LVs 
had significantly lower compliance than the normal control hearts, indicating diastolic 
dysfunction (Fig. 14) Furthermore, compliance in the intact LV did not increase after 
repeated LV volume ramps. 
 
The Frank-Starling mechanism is affected in the GRMD heart. The Langendorff 
preparation allowed us to measure directly the ability of the LV to increase force in 
response to mechanical and pharmacological stimuli. LV stretch increases Pdev through 
the Frank-Starling mechinsm, involving increased myofilament sensitivity to Ca++ and 
actin-myosin overlap (Patterson, Starling 1914) In the intact GRMD heart, we found the 
this mechanism to be blunted at two levels. Normal hearts showed a consistent increase 
in developed pressure as LV volume was increased. When similarly stretched, GRMD 
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hearts showed no significant volume-related increases as a group, though individual 
hearts did show minimal response (Fig. 15) Furthermore, the high diastolic pressures 
required to distend the LV to these volumes were beyond the physiological range. 
Therefore, to the extent that the Frank-Starling mechanism was intact, loss of LV 
compliance rendered it inaccessible as a source of increased contractility. 
 
Figure 13.  GRMD LVs showed no acute loss of Pdev after stretch.  Left: Pdev immediately before 
and 5 minutes after initial volume ramp in seven GRMD hearts.  Right: ~45 minute LV pressure 
trace from a GRMD heart showing four consecutive volume ramps at 0, 10, 33, and 100 µg/L 
epinephrine doses. 
Figure 14.  GRMD hearts have reduced LV compliance.  a) LV diastolic pressure-volume 
relationships in seven GRMD (red) and four normal control dogs (blue).  Black points indicate 
average pressure and volume before and after LV stretch ± 1SD.  b) LV compliance in the 
same hearts.     
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GRMD hearts lose inotropic reserve. The normal circulatory system reacts to increases 
in metabolic demand by increasing sympathetic and decreasing parasympathetic 
stimulation of cardiac myocytes, which increases contractility and heart rate together. 
Loss of reserve in failing hearts is commonly associated with autonomic dysfunction - 
increased sympathetic, decreased parasympathetic tone at rest. and elevated resting 
heart rates (Triposkiadis et al. 2009). Heart rates in vivo under the same dose of 
inhalational anesthetic were slightly higher in GRMD dogs than in normal dogs. Since 
the Langendorff preparation isolates the heart from autonomic control, we would expect 
a failing heart to beat more slowly when removed from the setting of neurohormonal 
stimulation. Indeed, the difference in HR seen in vivo was reversed in isolated hearts. 
After defibrillation, all hearts assumed an unpaced sinus rhythm, but isolated GRMD 
hearts had much lower baseline heart rates than normal control hearts (Fig. 16).  
Figure 15. Frank-Starling mechanism is blunted in GRMD LVs.  Pdev as a function of LV 
volume in seven GRMD and four normal control hearts.  A significant increase in Pdev was 
observed in normal, but not GRMD hearts when LV volume was increased.  
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To investigate the ability of GRMD hearts to respond to neurohumoral stimulation, we 
added epinephrine in increasing concentrations to the cardiac perfusate. In spite of lower 
baseline heart rates, GRMD hearts showed proportional increases in HR not significantly 
different than normal hearts. However, inotropic and lusitropic responses to epinephrine 
was severely blunted. As a group, GRMD hearts produced baseline developed 
pressures (Pdev), and rates of force development (+dP/dt) and relaxation (-dP/dt) similar 
to normal hearts. At the highest epinephrine concentration, both parameters increased 
by approximately 3 fold in normal hearts, compared to approximately 1.5 fold in GRMD 
hearts (Fig. 17). 
 
Inotropic reserve correlates with chronotropy and Frank-Starling effect. All but two 
animals in this study were over a year old at the time of euthanasia, an age when the 
skeletal musculature in most GRMD dogs are at an advanced state of disease. 
However, the degree of variability associated with the model allowed us to correlate 
different functional parameters. The ability of hearts to increase Pdev in response to 
epinephrine strongly correlated with chronotropic, and Frank-Starling response, 
suggesting a common mechanism. However, there was no correlation between diastolic 
and systolic function (Fig. 18).  
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Figure 16. GRMD hearts have altered chronotropy.  Heart rates (± 1SD) from seven GRMD and 
four normal hearts in vivo and under anesthesia (2% isoflurane) and during un-paced sinus 
rhythm in the Langendorff system.  HR increased with epinephrine dose in all hearts, but 
GRMD hearts had a lower starting point.  
Figure 17. GRMD hearts have reduced inotropic and lusitropic response to beta-adrenergic 
stimulation.  A) Pdev in seven GRMD (red) and four normal control hearts (blue) at baseline and 
perfused with increasing concentrations of epinephrine.  GRMD hearts showed small but 
significant increases at each dose (p < 0.05).  Student’s t test (paired). B) Peak rates of force 
development (+dP/dt, closed circles) and relaxation (-dP/dt, Xs) in response to epinephrine 
dose in the same hearts.     
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Discussion. 
 
This work represents the first study of LV function in an isolated perfused intact heart 
from a dystrophin null large animal model. We found severe diastolic dysfunction in the 
form of reduced LV compliance and lusitropy. GRMD hearts were less able to increase 
Pdev in response to adrenergic stimulation or stretch, indicating the presence of systolic 
dysfunction as well. Both defects contribute to the loss of cardiac reserve. An important 
innovation was the integration of a broad mandrel at the base of the LV pressure 
transducing balloon, and the surgical modification of the mitral annulus with a high-
strength purse-string suture. The rigid attachment of the LV to the pressure transducer 
afforded by these modifications, allowed far higher preload pressures than previously 
possible. The resulting finding that dystrophin-null canine hearts tolerate levels of 
preload that would be expected to cause massive acute failure of cardiac myocytes 
based on recent studies of isolated cells, indicates that the ECM plays a protective role 
in the dystrophic heart.  
Figure 18.  Loss of inotropy correlates with loss of chronotropy (a) and Frank-Starling response 
(b).      
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Skeletal and cardiac muscle both suffer from progressive loss of contractile reserve and 
in both Ca++ dysregulation appears to be central to the pathology (Claflin, Brooks 2007). 
However, there are important differences between the two tissues in both in the causes 
and the downstream effects of altered Ca++. Years of study in skeletal muscle have 
identified dystrophin’s role in stabilizing the membrane, and transmitting force from the 
contractile apparatus to the extracellular matrix. In the absence of dystrophin, forceful 
contractions open tears in the sarcolemma, leading to a local influx of extracellular Ca++, 
which activates actomyosin cross bridges - causing further tearing (Petrof et al. 1993a, 
Claflin, Brooks 2007). Ca++ influx also activates necrotic and apoptotic pathways 
(Zamzami, Kroemer 2001). The result is an ongoing cycle of cell death and regeneration 
accompanied by chronic inflammation.  
Differences in excitation-contraction coupling in the cardiac myocyte suggest it 
could be potentially even more sensitive to rupture and necrosis: a small local Ca++ influx 
can directly trigger Ca++ release from the sarcoplasmic reticulum. Collagenase-isolated 
individual cardiac myocytes suspended between focally membrane-adherent carbon 
fibers have been observed to fail this way seconds after passive stretches to sarcomere 
lengths well within the physiological range (Yasuda et al. 2012, Townsend et al. 2010). 
However, we found no acute loss of force following even greater stretches in the intact 
LV. Furthermore, the relatively slow clinical progression of dystrophic cardiomyopathy, 
even in the face of continuous use, suggests that cardiac myocyte necrosis is a 
comparatively rare event in vivo (Eagle et al. 2007). 
What protects the myocardium from the cycles of necrosis and regeneration that 
characterize the pathobiology of DMD in skeletal muscle? Differences in force 
generating capacity could play a role. Unequal necrosis and/or regeneration in 
dystrophin-null skeletal muscle of type II fibers expressing fast-contracting, high ATPase 
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rate, myosin heavy chains such as IIa and IIx, results in a shift towards the 
predominance of type 1 fibers expressing the lower ATPase, slow-contracting MYH7 
myosin (Petrof et al. 1993b). Ventricular myocytes in large mammals normally express 
exclusively MYH7 myosin, and are therefore incapable of the higher stress-strain 
dynamics attributed to fast skeletal fibers. 
Central to the issue of force-related damage is the manner in which contractile 
reserve is ‘stored’ in the two muscle types. Force modulation in skeletal muscle is 
achieved primarily by increasing or decreasing the number of contracting myocytes via 
the Henneman principle. Very little contractile plasticity resides within the cell itself 
(Henneman, Somjen & Carpenter 1965). Prior to failure, the dystrophin-deficient skeletal 
myofiber is capable of developing near-normal specific forces, requiring near-normal 
levels of ATP synthesis (Petrof et al. 1993a). Individual skeletal myocytes, though they 
contract less frequently than cardiac myocytes, are repeatedly exposed to near-maximal 
forces and metabolic rates. A skeletal muscle-driven system analogous to the heart is 
the respiratory pump, which operates over a similar range of output in response to 
demand. In the GRMD respiratory system, reserve declines as the work of ventilation at 
rest is taken up by a progressively larger share of available muscle fibers leaving fewer 
to cope with elevated demand.  
The healthy mammalian heart can sustain a greater than fivefold increase in 
pressure-volume workload in response to metabolic demand. But unlike skeletal muscle, 
this reserve capacity resides at the level of the individual myocyte. Each cell contributes 
to systole over the entire range of cardiac outputs, and so at rest is exposed to a fraction 
of its maximum force generating capacity and ATP turnover is relatively low. If the loss of 
contractile reserve we see in the GRMD heart is due to dysfunction in the signaling 
processes involved in increasing contractility in response to stimulation, cardiac 
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myocytes may be inhibited from developing forces high enough to challenge dystrophin’s 
role as a membrane stabilizer and thus protected from the level of necrosis seen in 
skeletal muscle. Dystrophin may have other roles that impact myocardial contractility 
upstream of the sarcomere.  
Several elements of the present study support the view that the GRMD 
myocardium is incapable of maximal actomyosin cross bridge recruitment. The large 
drop in heart rate from in vivo to Langendorff indicates that the GRMD hearts are under 
a high level of sympathetic stimulation to meet even basal metabolic demands. When 
epinephrine was added to the perfusate, heart rates returned to their in vivo levels. Initial 
Pdev, on the other hand, was the same as in normal control hearts yet response to beta-
adrenergic stimulation was severely blunted. To further test the hypothesis that 
contractile dysfunction at the stage of cardiomyopathy studied here is due to a failure to 
recruit otherwise viable contractile apparatus and not due to its absence, it would be 
informative to measure total myosin content. If myosin content per gram of tissue is 
nearly equal between the two groups, it would suggest that the GRMD hearts are 
incapable of maximal recruitment.  
Loss of compliance during diastole presumably also prevents increased 
recruitment of actomyosin crossbridges by rendering the Frank-Starling mechanism 
largely inaccessible. Possible sources of the high diastolic tension seen in the present 
study include increased deposition of ECM components such as collagen, shifts in 
collagen isoform composition, titin isoform changes, and elevated levels of diastolic 
Ca++. In isolated cardiac myocytes, Ca++ influx from sub-lethal membrane rupture 
appears to be the source of high diastolic tension (Townsend et al. 2010, Yasuda et al. 
2012). However, in these assays, the ECM is destroyed, removing a potential linkage to 
the remaining components of the membrane-spanning dystrophin-associated protein 
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complex. The present study indicates that in vivo loading in the context of an intact ECM 
protects dystrophin-null cardiac myocytes from actulely lethal membrane tears. 
Furthermore, the high diastolic tension shared between carbon fiber-suspended mdx 
and GRMD isolated cardiac myocytes is not present in whole mdx LVs, which actually 
show increased compliance (Barnabei, Metzger 2012). Therefore, the cause of diastolic 
dysfunction in the intact heart is far from certain.  
The present study supports a view that the primary pathology in cardiac muscle 
is due in large part to persistent dysfunction in existing cardiac myocytes that may be 
caused by membrane stability-independent mechanisms that stem from the absence of 
dystrophin. Absence of dystrophin in the heart leads, potentially by way of multiple 
mechanisms, to an impairment of the individual cell’s ability to develop maximal force. 
This could account for the ability of the individual cardiac myocyte to be more resistant to 
damage than skeletal muscle in the absence of dystrophin. Therefore, any new therapy 
that improves contractility, but does not correct the primary molecular deficiency, runs 
the risk of exposing the cardiac myocyte to potentially damaging stresses.  
The ex-vivo, structurally intact, perfused and properly intsrumented myocardium 
from the GRMD dog has the potential to contribute much to our understanding of 
disease pathogenesis. In addition to being useful for exploring the mechanisms of heart 
failure in DMD, these approaches can provide much-needed endpoint measures for 
assessing the efficacy of experimental therapies. Several recent pre-clinical studies in 
the GRMD have tested candidate therapeutics targeted directly at the failing heart 
(Townsend et al. 2010, Su et al. 2012, Bish et al. 2012). However, there is a dearth of 
compelling evidence for functional improvement, as studies conducted in vivo are limited 
to indirect measures of cardiac mechanics with the heart operating over a narrow range 
of pressure-volume excursions and thus cannot address reserve capacity. Bish et al 
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observed minimal improvements in circumferential strain rates by cardiac MRI, but no 
change in cardiac echo measures, in spite of significant dystrophin expression after 
percutaneous transendocardial injection of AAV6 carrying an exon-skipping vector (Bish 
et al. 2012). In such studies, the ex-vivo approaches described here would allow for the 
precise and direct measurement of alterations in contractile plasticity and reserve.  
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Chapter 3: Does the High-Force MYH16 Myosin Heavy Chain 
Increase Susceptibility to Contraction Induced Injury? 
 
Introduction. 
 
In the following chapter I dicsuss an ongoing work concerning aspect of the disease in 
the GRMD dog that is not shared by its human counterparts. The observation that 
particular jaw muscles of GRMD dogs display signs of early and severe pathology before 
any other muscle group, provides a unique opportunity to test investigate a major aspect 
of dystrophin function: membrane stabilization in the face of high forces. In this chapter I 
discusses techniques and ongoing studies to test hypotheses about dystrophin function 
in these muscles. 
Though the majority of GRMD dogs are euthanized on a schedule related to a 
study endpoint, a common clinical reason for euthanasia in the GRMD colony is not 
respiratory or cardiac insufficiency, but loss of weight from an inability to eat. The reason 
for this is that the muscles used for chewing: the mandibular elevators - temporalis and 
masseter - reach an advanced state of pathology far earlier than other body muscles. 
The result is trismus, a progressive restriction of maxiumum jaw opening. Dogs that 
develop severe trismus require hand feeding (Fig. 19) (Valentine, Cummings & Cooper 
1989, Shimatsu et al. 2005). 
Although boys with DMD often present with malocclusions (misalignment of the 
upper and lower jaws), an inability to chew and swallow food is not an identified clinical 
problem and the mandibular elevators are not uniquely affected (Morel-Verdebout, 
Botteron & Kiliaridis 2007). Interestingly, there is an aspect to these particular muscles 
that is also divergent between humans and dogs. The predominant myosin heavy chain 
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expressed in canine jaw muscles, comes from the canine homolog of the MYH16, and is 
understood to be the highest force myosin in the mammalian genome (Toniolo et al. 
2008). Although it was so named because it was the 16th myosin heavy chain gene to be 
identified in the human genome, humans do not express a functional MYH16 protein; in 
2004 Stedman et al reported the fixation of a two base pair frameshifting mutation in the 
human ortholog of MYH16 unique to the hominid lineage (Desjardins et al. 2002, 
Stedman et al. 2004). 
In addition to the importance of this observation to the clinical care of the GRMD 
dog, the apparent correlation of a high-force generating myosin heavy chain, and early 
and severe muscle pathology, is intriguing as a place to investigate dystrophin’s role as 
a force transmission protein. The converse of this correlation already exists in muscles 
expressing the lowest-force myosin heavy chain: the extraocular muscles, which control 
the orientation of the eye. These muscles have been extensively studied in part because 
they appear to be spared in DMD (Khurana et al. 1995, Kaminski et al. 1992). In this 
chapter I will describe ongoing studies of these muscles aimed at testing the following 
Figure 19. Images of an eight month old GRMD dog and normal litter mate.  The narrow head,  
sunken eyes and prominent zygomatic arch in the GRMD show the reduction in mass of cranio-
facial musculature.     
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hypothesis: that muscle fibers expressing MYH16 are inherently more susceptible than 
their MYH16 (-) counterparts to contraction-induced damage in the absence of 
dystrophin. 
 
Study design.  
 
Relation of MYH16 expression to damage susceptibility. To address the question of 
MYH16, force and susceptibility to damage, I take advantage of a fundamental 
anatomical feature of mammalian muscle. In any given muscle in the body, muscle fibers 
expressing one or another myosin heavy chain isoform will predominate depending on 
the primary function of the muscle. For example, in humans the soleus muscle of the 
lower leg is primarily used for maintaining posture while standing, which means it is 
required to produce minimal forces over long periods of time. Therefore low-force, high-
endurance type-1 muscle fibers expressing the MYH7 myosin heavy chain predominate. 
However, every muscle contains multiple fiber types distributed throughout the body of 
Figure 20.  Left: Canine temporalis (top) and tibialis anterior (bottom) stained with ‘Loop 2’ 
MYH16-specific myosin heavy chain antibody.  Right: ClustalW aligned amino acid sequences of 
human sarcomeric myosins with canine and human MYH16.  Highly variable ‘Loop 2’ region is 
flanked by highly conserved AA sequence.  Purple shaded area denotes antibody peptide 
sequence. Note that human and canine MYH16 in this region are identical. 
 the muscle. This is the case in canine temporalis and masseter as
fibers express the high force MYH16, lower force myosin expressing fibers are 
intermixed. These low-force fibers act as an internal control, allowing me to quantify any 
differences in susceptibility to damage between fibers in the sam
 
 
A simple way to observe such a difference in susceptibility would be to measure 
the ratio of MYH16+ to MYH16
However, this approach does not take into consideration the confounding variable of 
regeneration, and multiple biopsies are invasive and risky to the health of the animal. I 
take an alternative approach. In their landmark 1993 paper in PNAS, Petrof, et al 
provided the first demonstration of dystrophin’s role in protecting the sarcolemma from 
contraction-induced damage (Petrof et al. 1993a). They used a small molecular weight 
Figure 21. 10µm cryosections from 
month old GRMD dog stained with hematoxylin and eosin (A,D), anti
MYH16 ‘Loop 2’ (green) (B,E), and anti
inflamation in temporalis as compared to quadriceps
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dye, administered to the interstitium of diaphragm muscle two hours after a bout of 
eccentric contractions, to identify fibers that had undergone sarcolemmal rupture.  
Rather than attempt to sort out the complex history of damage and regeneration 
in muscle samples at necropsy, I use transcutaneous electrical stimulation to induce 
contraction-induced injury in the temporalis and masseter muscles in situ two hours prior 
to necropsy while the dog is under general anesthesia. Since I stimulate unilaterally, the 
contra-lateral muscles serve as a control to differentiate stimulation-induced injury from 
background injury. Muscles from both sides are then frozen for future analysis. Instead 
of procion-orange dye, the indicator of membrane permeability in these studies is 
intracellular Ca++ detected by staining fresh frozen sections with alizarin red S (Novultra) 
To standardize the categorization and counting of alizarin red S positive vs. negative 
fibers, I employ image analysis similar to that used in chapter 2, and described in the 
methods appendix. Fibers positive for Ca++ will be further categorized by myosin heavy 
chain isoform expression by immunohistochemistry using isoform-specific antibodies. At 
the time of writing, muscle samples from 15 GRMD and 6 normal control dogs have 
been collected and frozen for future analysis. 
 
MYH16 antibody. A significant advance towards the study of MYH16 gene products was 
the development of a polyclonal antibody raised against a unique epitope of the MYH16 
myosin protein. The S1 domain of myosin is characterized by large sections of highly 
conserved amino acid sequence punctuated by a handful of highly variable regions. I 
chose an epitope common to both human and canine MYH16 protein sequence in the 
‘loop 2’ domain (Fig. 20). Loop 2 is a flexible surface loop in the region of the actin 
binding site and is thought to modulate the isomerization that accompanies the transition 
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from weak to strong actin binding during the actomyosin cross bridge cycle (Furch, 
Geeves & Manstein 1998). 
An early application of the ‘loop 2’ antibody shows early evidence of a correlation 
between muscle damage in the absence of dystrophin and MYH16 myosin content by 
fiber in cryosections. Figure 21 shows serial sections from two muscles taken from a 6 
month-old GRMD dog that suffered from trismus. H&E stained sections show the 
disparity in the hallmarks of DMD muscle. Signs of advanced fibrosis, inflammation, 
regeneration and ongoing necrosis can be seen in the temporalis while the quadraceps 
is almost indistinguishable from normal muscle. Sarcolemmal rupture in the temporalis, 
as seen by albumin staining, is limited to cells that also stain positive for MYH16 myosin. 
Fibers from the limb muscle are also negative for MYH16. 
 
MYH16 and the swallow reflex. MYH16 is also expressed in two muscles involved in 
swallowing: tensor veli palatini (tvp), and the internal pteragoids. Over several years of 
working with the GRMD dog, we have noticed that in addition to trismus, dogs with 
advanced disease also have difficulty swallowing. Manual examinations revealed an 
inflexible soft palate in the location of the tvp muscle. To better observe the swallowing 
process, we examined one GRMD dog with severe trismus, and one normal control dog 
using cross-table fluoroscopy as they attempted to swallow a bolus of food mixed with 
barium sulfate for visualization. The GRMD dog appeared to have difficulty in the phase 
of the swallow reflex during which the soft palate is lifted out of the way of the passing 
bolus. We plan further studies using this technique to better characterize swallowing 
pathology and to investigate the possibility of surgical intervention to improve it.  
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Discussion. 
 
MYH16. The evolution of a jaw specific muscle fiber type is not surprising considering 
the importance of acquiring and masticating food, and in the case of carnivores, food in 
the throes of a fight-or-flight response. The unique developmental origin of these 
muscles, in the first branchial arch mesoderm, provided an environment where the 
expression and isoform profiles could adapt independently of other muscle types. Due to 
the high caloric content of the carnivore diet, and the subsequently small amount of time 
spent eating compared to herbivores, these muscles would not need to have optimal 
bioenergetic efficiency or endurance, but rather the capacity to develop high specific 
forces. Prior to the discovery of MYH16, the jaw closing muscles of carnivores had long 
been recognized as possessing a unique fiber type and myosin isoform, and contractile 
studies had supported this view (Hoh 2002, Hoh et al. 2007, Qin et al. 2002). 
A locus for modification of contractile parameters is the actomyosin cross bridge 
cycle. The basic model of force production in muscle was first proposed by Huxley, and 
it has been continually refined since (Huxley 1957). As with other aspects of skeletal 
muscle, the basic steps of the actomyosin cross bridge cycle are highly conserved, and 
all sarcomeric myosins studied to date follow the same reaction scheme (Geeves, 
Holmes 1999). 
A highly simplified model of the actomyosin cross bridge cycle can be used to 
explain how actomyosin ATPase reaction kinetics can modify the force produced by a 
contracting muscle fiber. For example, the maximum unloaded shortening velocity of a 
fiber (Vmax) is determined by the rate at which Pi and ADP dissociate from myosin, 
allowing myosin to detach from actin, this rate constant is often referred to as g. The rate 
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at which actomyosin cross bridges weakly bound to actin isomerise, is thought to 
determine the rate at which actomyosin cross bridges strongly attach and begin to 
develop force, or ƒ. Together, these two rate constants, ƒ and g determine the 
proportion of actomyosin cross bridges in a sarcomere that are attached and generating 
force at a given time. Huxley's cross bridge model predicts that the fraction of cross 
bridges attached is given by ƒ/ (ƒ+g). Since the unitary force generated by a single 
actomyosin cross bridge is generally considered constant across skeletal myosin 
isoforms, this proportion is the major determinant of the force per cross sectional area, 
or specific force of a fiber. 
Several parameters of MYH16+ muscle fibers have been measured, most 
recently in Toniolo et al (Toniolo et al. 2008). In this study of single, 
permeabalized canine masseter fibers, Vmax was shown to be roughly equal to that of 
normal type II fast skeletal fibers from the same animal. However, specific isometric 
force was found to be about 40% higher than that of any other fiber type in the body. 
These findings support the supposition by Hoh et al that the MYH16 myosin possesses a 
fast ƒ combined with a slow to moderate g (Hoh et al. 2007). 
A contrasting example of attachment and detachment rates is given by the 
myosins powering “superfast” muscles such as those of the toadfish swimbladder, bat 
larynx, songbird syrinx, and rattlesnake tail shaker (Elemans et al. 2008, Rome et al. 
1999, Elemans et al. 2011). These muscles, used for sound production rather than 
locomotion or mastication have adapted to be optimized for high speed rather than high 
force and are thought to have very high g and more moderate ƒ leading to a far smaller 
proportion of attached actomyosin cross bridges during contraction. The mammalian 
MYH13, or extraocular myosin is also thought to fall into this category (Frueh et al. 
1994). 
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A cursory analysis of the amino acid sequence near the ATP binding site on the 
MYH16 myosin motor domain provides further evidence of a high ƒ/ (ƒ+g). Studies by 
Spudich et al and others have determined a possible role for a flexible surface loop near 
the ATP binding domain (Loop 1) in modulating the release of ADP and Pi (Uyeda, 
Ruppel & Spudich 1994, Kurzawa-Goertz et al. 1998). Their findings suggest that 
dissociation rate constants of these two byproducts from myosin are enhanced by 
longer, more flexible loops. MYH16 possesses a loop 1 domain that is ~40% smaller 
than any other skeletal myosin, with the potential to retard the kinetics of ADP and Pi 
release commensurate with a slow to moderate g. 
 
Dystrophin and force. Evidence of dystrophin’s force transmitting role was reported early 
on by Petrof et al, in a study of in vitro mdx mouse diaphram muscle contractility (Petrof 
et al. 1993a). In that study the degree of acute damage, as measured by myofiber 
permeability to the small molecular weight procion orange dye, was correlated with peak 
force, and not with number of contractions. Interestingly, the investigators made use of 
eccentric contractions to induce damage. In this kind of contraction, muscle is activated 
electrically while being forced to lengthen. In everyday locomotion, eccentric 
contractions are common as muscles are constantly being used as brakes in walking, 
running, descending stairs, etc. A large body of literature has grown out of the study of 
muscles as brakes, in part because it is in this mode of use that muscle fibers are most 
likely to be damaged. This is the case even in normal muscle, but dystrophin deficient 
muscle is especially susceptible to eccentric contraction injury. Part of the reason for this 
kind of injury can be explained by an intrinsic property of sarcomeric muscle, namely that 
fibers generate more specific force during lengthening contractions than they do during 
isomentric (zero length change) or shortening contractions. 
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The use of this kind of contraction by Petrof et al was for the purpose of 
maximizing damage by maximizing force, but the authors acknowledged the possibility 
of an intrinsic, force independent mechanism of damage coming from this form of 
contraction. Subsequent work has been done to understand the force-independent 
aspects of eccentric contraction injury. For instance, there is evidence that eccentric 
contractions cause weaker sarcomeres to overextend and pull apart, possibly stressing 
the sarcolemma locally (Allen 2001). Also, mathmatical models of the lengthening 
myofiber predict shear forces between the contractile apparatus and the sarcolemma, or 
local changes in cell volume, either of which could provide a possible role for dystrophin 
in this particular kind of contraction. Further support comes from sports medicine (Gao, 
Wineman & Waas 2008, Rasgado-Flores et al. 2004). The phenomenon of the repeated 
bout effect, where a bout of eccentric contractions protects against the harmful effects of 
subsequent eccentric contractions has been recently correlated to an upregulation of 
dystrophin and other cytoskeletal proteins (Lehti, Kalliokoski & Komulainen 2007).  
However, whether force itself or force-independent properties of stretch are more 
responsible for cell death in the absence of dystrophin remains unclear. There is 
evidence to support the view that specific force of contraction is the most important 
factor. It is has been demonstrated that though the damage is less severe, dystrophin 
deficient muscle is damaged even during non-eccentric contractions (Claflin, Brooks 
2007). There is a well documented shift in fiber type during disease progression from 
higher force fast fibers, to lower force slow fibers. This could in part reflect a bias in 
regeneration towards slower fiber types, but evidence exists that higher force fast fibers 
undergo necrosis at a higher rate (Kaminski et al. 1992). Furthermore, a recent study 
of the eccentric force generating capacity of human muscle fibers reported that although 
the isometric and shortening force generating capacities differed greatly by fiber type, 
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there was a convergence of specific force generation in the eccentric mode (Linari et al. 
2004). This would suggest that during an eccentric contraction slow and fast fiber types 
would undergo necrosis at equal rates, all else being equal. Since this is not the case, 
normal isometric and shortening contractions must contribute substantially to myofiber 
necrosis. In the case of the GRMD dog, jaw-closing muscles rarely see eccentric 
contractions as jaw-opening muscles are vastly overpowered by the closers.  
 These studies aim to test the hypothesis that MYH16 myosin heavy chain 
predisposes myofibers to contraction-induced injury in the absence of dystrophin. 
WHA?? Additionally, studies of the other MYH16 expressing muscles, the tvp and 
pteragoids, and how they contribute to the pathophysiology of swallowing are crucial to 
the nutritional maintenance of an important model of DMD.     
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Conclusion, Ongoing Work, and Future Directions 
 
Conclusion. 
 
The studies presented in this work serve two parallel aims. First, the techniques 
developed here strengthen the GRMD dog as a model for testing experimental therapies 
by providing a means to directly assess the function of the body’s two most important 
muscle-driven systems: the heart and respiratory pump. Insight into the morphology of 
the curiously pathologic muscles of the jaw and soft palate has the potential to lead to 
improvements in nutritional support. Second, the focus of these studies on the 
mechanics of intact muscle-driven organ systems provides a link between the pathology 
of a particular muscle or muscle cell, and the functional output of the system in which it 
acts.  
 That respiratory reserve declines as DMD progresses is well known. What this 
study adds is an understanding of how the mechanics of breathing are altered by 
processes unique to the different muscle groups involved. The diaphragm does not 
simply weaken, but undergoes a dramatic remodeling that while not understood, 
appears to allow the pump as a whole to continue to function at a reduced level. This 
observation could only be made by studying the function of the intact respiratory pump in 
isolation from the confounding influence of systemic disease, and raises important 
questions about the molecular and cellular processes that occur downstream of the loss 
of dystrophin, and how they might differ between muscles of varying function. 
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 The central observation made in the study of the isolated GRMD heart was that a 
well-accepted mechanism of the loss of cardiac reserve – necrosis of individual cardiac 
myocytes as a result of sarcolemmal rupture, may not be as central to the clinical 
pathophysiology as assumed. Left ventricular myocardium, in the setting of the intact 
heart, showed remarkable resistance to extreme preloads, countering studies of 
individual isolated cells. The innovation that made this observation possible was the rigid 
attachment of the mitral annulus around a specially designed mandrel at the base of the 
LV pressure-transducing balloon to prevent extreme preload pressures and contraction 
from ejecting it.  
All three systems studied in this thesis inform our understanding about the role of 
dystrophin in protecting muscle from forceful contractions. Possibly adaptive 
mechanisms in two of these serve to maintain organ function by effectively reducing 
forces individual muscle cells are exposed to. In the respiratory system this takes the 
form of a remodeled diaphragm that enables the respiratory pump as a whole to spread 
the load of respiration over a wider range of muscle. In the heart, a blunted ability to 
recruit actomyosin cross bridges and remodeling of the extracellular matrix protects 
cardiac myocytes from potentially damaging forces. The result is sustained life at a low 
metabolic rate at the expense of reserve capacitly. The muscles of the jaw and soft 
palate provide a counter example, where the necessity for high forces, and consequent 
employment of a uniquely powerful myosin heavy chain, is highly maladaptive.  
Although every DMD muscle has the same protein deficiency, the inherent 
variety in muscle size, shape and function results in the wide range of pathological 
states we see within a single organism. In turn, this variability in the pathology of 
individual muscles plays out in how the organ systems they serve become dysfunctional. 
In exploring this variety of use and pathological states among muscles, and correlations 
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between the two, we can gain insight into not only the disease, but the normal function of 
muscle and muscle driven systems as well.   
  
Ongoing work. 
 
Right ventricular cardiac trabeculae. Studies of Ca++ dynamics in the dystrophic cardiac 
myocyte have brought to light potential mechanisms to explain the contractile 
deficiencies observed in the present isolated perfused heart study (Williams, Allen 2007, 
Ullrich et al. 2009, Sarma et al. 2010). Actomyosin cross bridge recruitment in the 
cardiac myocyte is increased or decreased in large part by signaling mechanisms that 
modulate the magnitude of Ca++ transients in the cell. Dystrophin appears to play a role 
in the signaling pathways that modulate Ca++ transients at a number of points, but most 
of these studies have been done mdx cardiac myocytes that have been isolated in a 
process that destroys the extracellular matrix, confounding interpretations of Ca++ 
transients due to the membrane instability that is inherent in this technique. One 
potential mechanism of reduced Ca++ is impaired loading of the SR from reduced SR 
Ca++ ATPase2a (SERCA2a) gene expression in mdx hearts (Rohman et al. 2003). 
There are important differences between cardiomyopathy in mdx and humans 
(Barnabei, Metzger 2012). To date no one has studied Ca++ handling in the intact GRMD 
myocardium. I have begun a collaboration with Dr. Abigail Dean in the lab of Dr. Kenneth 
Margulies at the University of Pennsylvania. They have developed a system for 
measuring cardiac mechanics on excised right ventricular trabeculae. These free-
standing strips of myocardium are small enough to be maintained in oxygenated Ringer 
solution for several hours, and can be excised from the right ventricle after the heart has 
been removed from the Langendorff. Since diastolic and developed force can be 
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measured, as well as response to inotropic agents, these trabeculae can also serve to 
reinforce observations made in the whole heart (Williams, Allen 2007). But most 
importantly, the small size of trabeculae make possible two techniques for assessing 
defects in Ca++ transients. In healthy myocardium, the increased Ca++ influx from high 
extracellular Ca++ leads to increased SR Ca++ release (Quaile et al. 2007). A blunted 
response to increased bath Ca++ would suggest impaired loading of the SR. 
At the time of writing, trabeculae from five GRMD, two normal control, and one 
carrier heart have been studied. However, the trabeculum from one of the normal dogs 
developed comparatively little force, and failed to respond to beta-adrenergic stimulation. 
To summarize the preliminary results shown in figure 22, RV trabeculae exhibited both 
systolic and diastolic dysfunction similar to that seen in the whole hearts. Compared to 
the trabeculae from one normal and one carrier heart, the GRMD trabeculae had a 
blunted length-tension relationship, indicating a loss of Frank-Starling response. As in 
whole hearts, GRMD trabeculae also had a blunted response to the β-adrenergic 
stimulant isoproterinol GRMD when compared to the carrier, but not the normal control 
trabeculae. More normal studies are planned to control for these results. GRMD 
trabeculae show a blunted response to increases in interstitial Ca++.  
 
Non-invasive biomarker development. The studies described above and in the first two 
chapters have been used to assess respiratory and cardiac function at the time of 
euthanasia. In order to track disease progression in response to therapeutic intervention, 
it is crucial to apply what I have learned from these studies to the development of 
minimally invasive assays that can be performed at multiple time points throughout the 
life of an in individual animal. In the case of respiratory function, the instrumented 
doxapram studies described in chapter 1 are safe enough to perform in this way. To date 
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we have administered doxapram to three dogs undergoing a course of survival 
anesthesia for unrelated studies with no ill effect. The dogs studied in chapter 1 were all 
in a fairly advanced state of disease. Serial measurements in individual animals over a 
broad range of ages will provide the power to correlate respiratory parameters with other 
markers of disease state. GRMD dogs in therapeutic studies are routinely anesthetized 
for hind-limb force-transduction and muscle biopsies. Plans are under way to perform 
doxapram studies at the same time on a cohort of young dogs at a minimum of three 
time points as they age.  
 
Serial non-invasive cardiac assessment. Since the measurements of intact myocardium 
so far described can only be made at the time of euthanasia, other less direct methods 
of cardiac assessment must be developed to compare to the more direct endpoint 
measures. Early on I attempted to test the hypothesis that the autonomic dysfunction 
that accompanies loss of reserve would manifest, as it does in boys with DMD, as a 
change in a certain component of heart rate variability (HRV) (Lanza et al. 2001). 
Sympathetic and parasympathetic signaling are modulated on different timescales. The 
relatively fast modulation of parasympathetic signaling results in variations in heart rate 
that are in synch with respiration, so called Respiratory Sinus Arrhythmia (RSA) Loss of 
parasympathetic tone at rest is a common indicator of loss of cardiac reserve in failing 
hearts, and is reflected in a loss of RSA as measured by Fourier transformation of heart 
rate (Berntson, Cacioppo & Quigley 1993). Measuring RSA in the relaxed GRMD dog 
was relatively simple, but I was unable to coax the normal control dogs in to a similar 
restful state, making comparison impossible. A possible solution to this problem is to use 
jacketed telemetry – EKG leads and a transmitter protected by a tight-fitting coat – to 
collect data over a period of hours or days.  
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Figure 22.  Isolated RV trabeculae recapitulate the behavior of the intact LV.  Response of 
diastolc and developed tensions in 5 GRMD (combined, red), two normal (individual, blue), and 
one carrier trabeculae (purple) when exposed to isopreterinol, increasing strain, and increasing 
bath [Ca++]. 
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A more direct approach to measuring autonomic dysfunction in a non-invasive manner, 
is to use the sympathomimetic drug dobutamine in anesthetized dogs before or after the 
survival doxapram tests described above, and assess its effect using cardiac echo. 
Cardiac echo has been used to assess cardiac abnormalities in the GRMD dog (Yugeta 
et al. 2006, Chetboul et al. 2007). However, as in humans, standard indices, such as 
end-diastolic/end-systolic volumes and cardiac output, are largely normal at the stages 
of disease where therapeutic efficacy will be assessed (Moise et al. 1991, Yugeta et al. 
2006). Only by using more qualitative techniques, such as speckle tracking, do 
differences in left ventricular function between GRMD and normal dogs emerge 
(Chetboul et al. 2007, Takano et al. 2011). In the isolated heart, loss of reserve was 
largely due to a loss of inotropy. I expect dobutamine to uncover quantitative deficiencies 
in inotropy in vivo that can be measured by echocardiography. Efforts along these lines 
are already underway. In several dogs (7 GRMD, 4 normal, and 1 carrier), under 
isoflurane for other purposes, we have administered dobutamine and imaged the heart 
using 2D and 3D echo. Analysis is ongoing, but initial estimations of stroke volume from 
2D images indicate that the GRMD hearts have a blunted inotropic response to 
dobutamine.  
 In addition to these studies of systolic function, I am also interested in applying 
non-invasive techniques to assess changes in diastolic function. Although the degree to 
which preload can be increased in vivo is limited (as discussed in chapter 2) small 
increases are possible. I plan to investigate two simple methods. First, hydrostatic 
pressure at the level of the vena cava, and thus LV preload, can be increased by tilting 
the body to a head-down, legs up position. This can be done in a repeatable manner by 
the use of a tilting table. The same effect can be accomplished by applying pressure to 
the lower body either with a large pressure cuff, or a pressure chamber. Either of these 
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methods could be employed relatively quickly during an anesthetic course, with little or 
no risk to the animal. Again, echocardiography would be used to estimate end-diastolic 
volumes. 
Combined with Langendorff and trabeculae studies done at the time of 
euthanasia, I expect these serial lifetime measures to be a powerful tool for tracking the 
progression of cardiomyopathy in the GRMD dog, and for measuring the efficacy of 
therapeutic interventions.  
Future directions. 
 
In a disease as devastating as muscular dystrophy, in particular DMD, it is easy to lose 
sight of how the absence of elements of the DGC – such an apparently critical link 
between the contractile apparatus and the extracellular matrix – could be compatible 
with life at all. However, the studies discussed here have uncovered elements of the 
pathophysiology of the disease that appear to be protective. One example is the 
mechanism or mechanisms by which the absence of dystrophin reduces the cardiac 
myocyte’s abililty to fully tap into potentially damaging force-generating capacity. We see 
a similar loss of inotropic reserve in other forms of heart failure, and it makes sense from 
an evolutionary perspective that cardiac muscle would be under greater pressure to 
have fail-safe mechanisms in place to protect against overuse injury. In this way these 
studies inspire the following question. Of the many changes that occur in muscle as the 
result of the loss of dystrophin, which are maladaptive, and which are protective? 
An element common to all three muscular systems studied here – cardiac, 
respiratory, and mandibular – is that to the passive mechanical properties of the muscles 
involved are altered. In the jaw this manifests as maladaptive trismus, but in the cardiac 
and respiratory pumps, there is significant evidence that alterations in passive properties 
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protect both organs from further loss of function. The stiffened LV is at least temporarily 
protected from Frank-Starling related increases in potentially damaging actomyosin 
cross bridge recruitment, and the remodeling of the diaphragm appears to prevent 
inefficient paradoxical motion. A top candidate for the cause of these changes, and one 
that is common to all three tissues, is fibrosis. Fibrosis is a loosely defined term used to 
describe an accumulation of extracellular matrix (ECM) proteins, in particular collagen, in 
the interstitial spaces of muscle that occurs in almost all myopathies (Gillies, Lieber 
2011). In DMD, fibrosis is a hallmark characteristic of all muscles, but varies in degree 
from muscle to muscle (Alexakis, Partridge & Bou-Gharios 2007).  
The causes of fibrosis in DMD are not well understood, although several 
pathways of both excess ECM protein production, and reduced degradation have been 
implicated. On the production side, fibroblasts and other cells are stimulated to secrete 
collagen and other ECM proteins by Transforming Growth-factor β (TGF-β which is 
present in high abundance due to ongoing rupture and necrosis of myocytes. TGF-
βsignaling is thought to play a role in both DMD fibrosis, and in the fibrosis that 
accompanies diastolic heart failure (Leask 2007). In addition expression of two proteins 
that sequester TGF-β, biglycan and decorin, is altered in DMD (Zanotti et al. 2005). 
Degradation of ECM could also be altered in Duchenne by altered expression and 
activity of matrix metaloproteinases (MMP) and their inhibitors, which regulate the 
turnover of ECM proteins (Border, Noble 1994). Drugs that target fibrosis at multiple 
levels are being investigated as potential therapeutic targets for DMD (Zhou, Lu 2010).  
Fibrosis in DMD and other myopathies is most often quantified by staining 
transverse sections of muscle for collagen, as in the present study of respiratory muscle, 
or by high-performance liquid chromatography (HPLC) analysis of hydroxyproline 
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content in homogenized tissue (Stedman et al. 1991). Although both approaches provide 
a decent approximation of non-specific collagen content, neither gives much information 
about how the altered ECM affects muscle function. Because of the important role it 
appears to play in preserving reserve capacity in the heart and respiratory pump, I am 
particularly interested in investigating how ECM remodeling alters the mechanical 
properties of particular muscles in DMD. The potential for therapeutic targeting of fibrosis 
makes addressing this question in the heart and diaphragm is especially crucial.  
A central difficulty of understanding the influences of ‘fibrosis’ on muscle 
mechanics in DMD is that even in healthy muscle we do not have a precise 
understanding of how the ECM is organized to transmit contractile forces (Gillies, Lieber 
2011). This is in part due to the complexity and diversity of collagen networks in the 
basement membrane and ECM. Collagen comprises a large family of proteins 
characterized by containing domains with repetitions of the proline-rich tripeptide Gly-X-
Y (Gelse, Poschl & Aigner 2003). At least ten isoforms are expressed in muscle at 
different times during development. Collagen in muscle can be roughly classified into 
two groups: the fibril-forming collagens, primarily types I and III, and to a lesser extent, 
V, XII, and XIV in muscle, which make up the ECM and matrix-forming (IV and VI), which 
are located closer to the sarcolemma in the basal lamina (Gillies, Lieber 2011). These 
structures work in concert to confer force generated in the contractile apparatus to 
tendons and bones. Their complexity is not surprising considering that they have to be 
both strong enough to transmit extreme forces, yet still flexible enough to deform as the 
muscle cell changes shape. All this must be done without conferring shear forces on the 
delecate sarcolemma. 
Passive tension in sarcomeric muscle has two major sources: the giant half-
sarcomere spanning protein titin, and the ECM. Differentiating the relative contribution of 
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these two sources of tension has been challenging, but recently developed techniques 
have illuminated an important difference between the two (Meyer, Lieber 2011, Gillies et 
al. 2011). The passive elastic property of intact muscle as a whole is non-linear. Single 
fibers of the contractile apparatus alone demonstrate that, over the physiological range, 
its contribution is linear. However, when all elements of the contractile apparatus are 
removed in a process that leaves the ECM intact, the remaining structure has a non-
linear stress-strain relationship.  
This finding retrospectively shines light on an earlier landmark observation in the highly 
fibrotic diaphragms of aged mdx mice. Passive stretches in strips from these muscles 
revealed a highly non-linear stress/strain relationship compared to normal mouse 
diaphragm (Stedman et al. 1991) The ability to measure mechanical properties of the 
ECM alone opens avenues for future study in the GRMD, and how they may differ 
between muscles of differing function. These studies could be coupled to western blot 
and IHC analysis of individual collagen isoforms, as well as gene expression studies of 
ECM components and relevant transcription factors to draw connections between 
isoform content and distribution on the one hand and passive mechanical properties on 
the other. 
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Appendix I: Materials and Methods 
 
 
From Chapter 1: Respiratory measurements. 
 
Animals. This study included 34 clinically stable dogs affected with Golden Retriever 
muscular dystrophy (GRMD), and 20 unaffected control dogs, either from the GRMD 
colony or mongrel, and ranging from 4 to 18 months of age. 7 GRMD and 5 normal 
control dogs were included in doxapram studies under anesthesia at the time of 
necropsy. All animals used in this study were cared for and used humanely in 
accordance with the requirements specified by the Internal Animal Care and Use 
Committee (IACUC) at the University of Pennsylvania, the Animal Care and Use 
Committee (ACUC) at the University of North Carolina, or the Animal Care and Use 
Committee (ACUC) at Wake Forest University and in accordance with the Guide for the 
Care and Use of Laboratory Animals (National Research Council, NIH Publication No. 
85-23, revised 1996). RIP studies of awake dogs were conducted at the Perelman 
School of Medicine, University of Pennsylvania, the University of North Carolina, and 
Wake Forest University. All doxapram studies were conducted at the University of 
Pennsylvania. All dogs were a part of other research projects.  
 
Respiratory inductance plethysmography (RIP). RIP traces were generated by 
inductance bands embedded in the Lifeshirt® jacketed telemetry system (Vivometrics, 
Inc.) and analyzed using Vivologic® software (Vivometrics, Inc.) Shirts from a range of 
sizes were fitted to dogs with the primary aim being proper location of rib cage (RC) and 
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abdominal (AB) inductance bands. The AB band was located at the level of the fourth 
rib, and the RC band just caudal to the rib cage. To calibrate the RIP system, a 
qualitative diagnostic calibration (QDC). was performed for each measurement session 
as described (Murphy, Renninger & Schramek 2010, Sackner et al. 1989). This process 
corrected for variations between bands. Breath by breath analysis from an Omida Excell 
210 anesthesia machine (Datex, Inc) over a period of 60 seconds of quiet breathing was 
used to calibrate RIP bands for real tidal volumes.  
 
Pressures. Gastric pressure (Pgas) and esophageal pressure (Pes) was measured as 
described using balloons constructed from an Intra-Aortic Balloon Pump (IABP) coronary 
perfusion support system. (Fideltity, Datascope, Inc.) (MILIC-EMILI et al. 1964). These 
polyethylene balloons have the advangage of being mounted on long flexible cannulae. 
The balloon material is inelastic, and therefore does not contribute to Pgas or Pes as a 
result of any inherent recoil. The balloons were connected to calibrated pressure 
transducers, the output digitzed with a MP150c data acquisition system (Biopac 
systems, Inc.), and analyzed using Acqknowledge software (Biopac systems, Inc.). Inter-
breath pressures were set to zero during restful breathing. Trans-diaphragmatic 
pressure (Pdi) was calculated by subtracting Pes from Pgas. 
 
Anesthesia and doxapram studies. Dogs were induced with dexmedetomidine 
hydrochloride (375 mcg/m2) (Pfizer Animal Health) before being masked down with 
isoflurane (Baxter Healthcare, Deerfield, IL), intubated, and maintained at 2% 
continuously throughout the study in a laterally recumbent position. Gastric and 
esophageal balloon catheters were placed, and the Lifeshirt® jacket was fitted to the 
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dog. Doxapram hydrochloride (Baxter Healthcare, Inc.) bolus was administered via 
saphinous vein at 1mg/kg followed by a second dose of 2mg/kg five minutes later.  
 
Histology. The length of the costal muscular diaphragm was measured in vivo at least 
three places through an incision in the abdominal wall at necropsy. To determine 
sarcomere length at these dimensions, strips were clamped with two-headed biopsy 
forceps, excised, and fixed in 10% formalin. Diaphragm thickness was measured once at 
this point. Fixed tissue blocks were sectioned longitudinally, stained with hemotoxylin 
and eosin (H&E) and imaged at 20X. Sarcomere length determined by measuring the 
length of 10 sarcomeres and dividing by 10. In addition, diaphragm, external and internal 
intercostal, abdominal wall and tibialis anterior muscle blocks were excised and frozen in 
liquid N cooled isopentane. These were later thawed and fixed in 10% formalin for 24 
hours prior to paraffin embedding and sectioning at 7µm. Sections were stained with 
hemotoxylin and eosin and picrosirius red and imaged at 20X in bright field. Images 
were analyzed for collagen cross-sectional area using Image Pro 7. Image files were 
converted from the RGB color model to the YIQ color model. Channel Y (luminance) was 
extracted from the YIQ image. The extracted Y channel is an 8bit greyscale image. 
Image segmentation was histogram based, double-threshold intensity ranges were set 
to: Contractile apparatus (0-140), Collagen (140-205). Data was exported to Excel for 
further analysis. 
 
Statistics. All data in figures is presented as means ± SDEV. Significance between 
groups was tested with paired or unpaired Student’s t-test as appropriate.  
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From Chapter 2: The Langendorff heart. 
 
The object developing the isolated, perfused heart preparation was to create an 
environment in which the whole heart could be studied independent of confounding 
factors present in vivo. A heart that has compromised reserve, may function normally 
under resting conditions, but it is necessarily unable to increase its output in response to 
increasing metabolic demand as well as a healthy heart. Determining in what way the 
heart is deficient, or directly measuring reserve capacity at all, can be impossible in vivo. 
In DMD, this is especially true, since the systemic pathology severely limits the extent to 
which metabolic rate can be increased.  
 
A brief history. The concept and first experiments with the isolation of a living heart from 
the corporeal circulation and maintenance with extracorporeal support date back to 
1846, when german physiologists Carl Ludwig and his student F. Wild connected the 
aorta of a mammalian heart to the corotid artery of a living animal (Wild 1846). The 
concept was later refined and described by Oskar Langendorff, after whom the 
preparation was named (Langendorff 1895, Zimmer 1998). 
More than seventy years separated Langendorff’s original isolated perfused 
heart, and the next major step in isolated heart studies: the development of the so-called 
working heart preparation by American physiologist James Neely (Neely et al. 1967). 
Work here is the formal definition: force multiplied by distance traveled – or in this case 
pressure multiplied by change in volume. In it’s natural setting, the heart pumps blood by 
changing the volume of a ventricle and forcing blood into the circulation. The forces 
acting against this change in volume are determined by the complex interplay of 
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vascular resistance, inertia, filling pressures, etc., which, together with contractile 
function, determine the shape of the ventricular pressure-volume relationship. In a true 
working heart preparation, a ‘mock circulation’ mimics the forces the ventricle ‘sees’ in 
vivo. Since work can therefore be measured, this method allows for the study of 
metabolic as well as contractile function. 
The true Langendorff, or non-working heart preparation is simpler. Here, 
ventricular volume is determined by the experimentor and held constant, and pressure 
alone is measured. Since there is no change in volume during systole, the ventricle 
technically does no work. The slope of systolic and diastolic pressure-volume 
relationships can be determined by step-wise increases in LV volume. Since we were 
primarily interested in the contractile function of the LV, we chose the non-working 
system for the GRMD hearts. And since the metabolic demand of isometric contraction 
is far lower, we could more reliably meet those demands with our perfusion system.  
 
Components of the system. Figure 23 is a schematic drawing of the main components of 
our Langendorff perfusion apparatus. The system consists of a perfusion circuit charged 
with sanguinous perfusate, and a left-ventricular balloon of variable volume filled with 
isotonic ringers solution and connected to a second pressure transducer. Beginning in 
the main reservoir, the perfusate flows by gravity and suction to the centrifugal pump, 
the speed of which is adjusted to provide a constant pressure of ~80mmHg at the aortic 
valve. From the pump the perfusate passes through the membrane oxygenateor and 
heat exchanger, a particulate filter and bubble trap, past a pressure transducer mounted 
at the height of the coronary arteries, and from there into the aortic cannula. The closed 
aortic valve shunts flow into the coronary arteries, perfusing the heart. From there blood 
flows out of the coronary veins, exits the heart and returns to the reservoir.  
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A central feature of the perfusion circuit is the membrane oxygenator, a device 
normally used in the clinical setting of cardiopulmonary bypass surgery. We used two 
types of membrane oxygenationator (Trillium Affinity NT, Medtronic, Inc.; Apex, Cobe 
Cardiovascular, Inc.), both designed to provide full gas exchange support to a 
normothermic 200lb male patient undergoing cardiac surgery. These membrane 
oxygenators also incorporated integral heat exchangers, through which we recirculated 
water from a bath heater (Haake A 28F/SC 100,Thermo Fisher, Inc.) to maintain 
perfusate temperature at 37˚C. 
  
 
 
Figure 23.  Schematic drawing of the Langendorff isolated perfused heart preparation.  Not 
shown is the tight purse-string suture attachment of the mitral annulus to the neck of the LV 
balloon. 
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A significant challenge was the design of the aortic and LV cannulae and their support 
systems. These had support the weight of the heart and, in the case of the LV balloon 
canula, to withstand the significant forces generated during systole without migration or 
expulsion. Starting material for the aortic cannula was a modified aortic perfusion 
cannula (Ez Glide, Edwards Lifesciences, Llc.), which had a convenient lip over which 
the aorta could be tied without slipping. For the LV balloon cannula, we began with a 
large venous cannula (Medtronic, Inc.) and cut it just below the lowest set of vent holes. 
We used epoxy and a series of silcone and rubber o-rings to form a mandrel to retain the 
mitral anulus. Finally a latex balloon (Trojan, inc.) was fixed with multiple rubber bands 
over the mandrel. These two cannulae were mounted in a plate of clear acrylic through 
holes lined with cylinders made from plastic 10 and 30ml syringes. These allowed the 
height and proximity of the two cannulae to be adjusted depending on the size of the 
heart. Once adjusted the cannulae were fixed in place with removable cable ties. 
 The reservoir, along with the cannula support plate, was designed to enclose the 
entire heart to minimize both heat-loss, and loss of perfusate. We built the reservoir from 
a 3L clear plastic containment vessel scavenged from the disposable components of a 
cell-saver (LN205, Haemonetics, Inc.). This particular part was chosen for it’s convenient 
volume markings, and integral drain port, but any clear similar sized vessel would have 
done. A second vessel was integrated into the circuit via a side-port downstream from 
the main reservoir. We used this to exchange the perfusate during the course of an 
experiment. 
 To provide perfusion pressure, we used a centrifugal pump normally used in 
cardiopulmonary bypass, and designed to minimize hemolysis. Pressure at the level of 
the coronary arteries was finely adjusted by changing pump rotation rate. Tubing 
throughout was silicone with an inner diameter of 0.5 inches.    
84 
 
 
Components of the perfusate. Perfusate was a modified Krebs-Henseleit buffer 
containing (mmol/L): CaCl2 (1.5), glucose (5.5), KCL (4.7), MgSO4 (1.66), NaCl (118.0), 
NaH2PO4 (1.18), NaHCO3 (24.88), and Na-pyruvate (2.0) in H2O, to which was added 
20% heparinized whole blood. Because of the bicarbonate buffer, a mixture of 95% 
oxygen and 5% CO2 was flowed through the membrane oxygenator to maintain pH of 
7.4. We chose a sanguinous perfusate to enhance oxygen carrying capacity, and to give 
a continuous visual indicator of perfusate oxygenation and oxygen extraction. Figure 24 
shows the change in color between the largely de-oxygenated venous blood prior to its 
first pass through the membrane oxygenator. Evidence that the system provided 
adequate oxygen delivery was supported by the observation that after this initial pass 
through the oxygenator and the coronary circulation, perfusate color in the reservoir 
remained bright red throughout the case; this was expected given the relatively low rate 
of ATP hydrolysis by the isometrically contracting myocardium.
Figure 24.  Image of the membrane oxygenator showing color change of sanguinous 
perfusate from deep to bright red. 
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Procurement and mounting of the heart. Hearts were procured in much the same way as 
would be for live organ transplant. A significant difference, however, was the 
requirement that the animal be euthanized prior to opening the chest. In a mechanically 
ventilated animal under 3% isoflurane we made a single neck incision to expose the 
external corotid artery, and jugular vein. Into the jugular, we inserted as far as the right 
atrium the largest wire-wrapped venous cannula possible (16-22fr), and clamped it off. 
We then inserted a specially fabricated cannula into the carotid, also clamped. The 
animal was then rapidly vaccum exsanguinated through the venous cannula, while cold 
Krebs-Henseleit solution was flowed into the carotid artery by gravity flow. To focus the 
cold solution at the level of the heart, we lifted the legs and lower body off the table. 
When we could no longer detect an EKG signal, the chest and pericardium was opened 
and cold Krebs-Henseleit was poured directly on the heart. Once the heart and lungs 
were removed, we used a 60ml syringe to perfuse the heart with cold cardioplegia 
solution via the clamped aorta. The heart was then moved to an ice-filled cooler for 
storage. 
The dissection of the heart prior to mounting in the perfusion apparatus was 
performed on a cold operating field. After carefully dissecting the heart and major 
vessels away from the lungs, trachea and esophagus, we weighed the heart. The aortic 
arch was then transected near the first major branch vessel, and a purse string suture 
was placed in the aortic wall as shown (Fig. 25a). Next the left atrium was opened by 
extending one incision to connect the ostia of the four pulmonary veins. The mitral 
chordae tendonae are incised and the tips of the mitral valve leaflets are removed (Fig. 
25b). A pledgeted purse string suture is placed around the mitral annulus, with a 
Remmel tourniquet applied to the free ends (Fig. 25c,d). The apex of the heart is incised 
and a third pledgeted purse string suture is placed to secure a left ventricular vent, 
86 
 
fashioned to minimize injury to the latex balloon (Fig. 25e). The heart was mounted by 
advancing the two cannulae, described above, into the aortic root and left ventricle and 
tightening the respective purse strings to prevent cannula migration (Fig. 25f,g). 
 
Figure 25.  Major steps in the preparation of the heart for mounting to the Langendorff 
apparatus.  a) Posterior view of the heart. LV and Aortic root are visible. b) Close-up view of the 
aortic root. Purse-string suture being applied. c) View of the mitral annulus through the open left 
atrium.  Removal of mitral valve leaflets.  d) Purse-string suture being applied to the mitral 
annulus for the purpose of retaining the LV balloon cannula.  e) Completed mitral purse-string. 
f) Apical LV vent prevents accumulation of perfusate between the balloon and LV walls. g) LV 
balloon cannula (left) and aortic cannula in view. h) The aortic root is pulled up over the aortic 
cannula.  
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Perfusion and warming. From initial cooling in vivo, until the moment of being connected 
to the Langendorff apparatus, hearts were maintained on ice and were not allowed to 
warm until exposed to oxygenated perfusate. We recirculated 800ml of Krebbs-Hanselite 
perfusate for several minutes until equilibrated at 37˚C prior to connecting the aortic 
cannula to the circuit. Once the connection was made, and perfusion pressure adjusted 
to ~80mmHg, we allowed a period of ten minutes for the heart to equilibrate to 37˚C. 
During this time, 200ml of heparinized whole blood was added to the reservoir, and care 
was taken to observe the color change in the coronary arteries and veins as clear 
perfusate was replaced by the perfusate-blood mixture. In most cases, during this 
warming period we would begin to observe signs of coarse ventricular fibrulation. 
Occasionally, hearts would spontaneously enter sinus rhythm, but most often 
defibrulation was required. We would repeatedly defibrulate until an identifiable QRST 
pattern was observed (Fig. 25). Up to this point, the LV cannula and balloon were left 
empty. To fill the balloon, we used Krebs-Henseleit solution in case of balloon rupture, 
warmed to 37˚C to fill the LV system and purged it of air.  
 
Figure 26.  An ECG image from defibrillation paddles on a heart in sinus rhythm showing a 
recognizable QRS pattern.  
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LV volume ramp. We increased left ventricular volume by steps. Step size was 1,2, or 4 
ml, and was determined by taking into consideration the size of the heart, and whether it 
came from a GRMD or normal control animal. Volume was increased until one of the 
following criteria was met: we reached a volume at which developed force dropped from 
the previous volume, arrhythmias occurred, or preload pressure exceeded 50mmHg 
(Fig. 27).  
 
Figure 27.  A ten minute LV pressure trace showing elements of the Langendorff protocol.  
Epinephrine is added at (*).  Developed pressure and heart rate increase to a plateau within a 
few minutes.  LV volume is increased by steps beginning at (†). 
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Beta-adrenergic stimulation. After the initial volume ramp, we added epinephrine 
(American Reagent Inc. Shirley, NY 11967) to the perfusate reservoir and stirred to mix. 
We monitored the LV pressure trace until increases in heart rate and developed force 
reached a plateau. This usually took about 5 minutes depending on the rate of perfusion. 
[8] We began with a concentration of 10µg/L, and subsequently added 23µg/L and 
67µg/L for calculated final concentrations of 10, 33, and 100µg/L. 
 
Removal of the heart from the perfusion circuit. In order to preserve the right ventricular 
trabeculae for subsequent study, we pleged the heart in place via the perfusion circuit. 
This was done by clamping between the filter/bubble trap and the perfusion pressure 
port, [4] and quickly injecting three to five 60ml syringes full of cold cardioplegia solution 
via a four-way stopcock at the junction of the perfusion circuit and the pressure line.[4] 
This resulted in complete cardiac arrest within a minute or so. LV volume was then set at 
a known value for later fixation with 10% buffered formalin and the heart, with aortic and 
LV cannulae attached, was returned to the cold dissection field for dissection of RV 
trabeculae (described below). 
Figure 28.  Example trace showing LV pressure in the time domain (top) and its derivitive 
(bottom).   Maximum and minimum derivative values represent (+)dP/dt and (–)dP/dt 
respectively. 
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Response of heart rate to epinephrine. The LV pressure record (fig) provided a single 
continuous source for LV pressure in the time domain. Acknowledge software allowed us 
to easily measure heart rate, LV compliance, developed pressure, and rates of force 
development and relaxation. The response of heart rate to epinephrine dose was 
measured by averaging three sequential R-R intervals. In a heart beating in sinus 
rhythm, the variation between these three was typically on the order of less than 1%. We 
took our measurement at each epinephrine concentration just prior to the volume ramp.  
 
Analysis of LV compliance. Diastolic pressure was measured during the initial baseline 
volume ramp. Measurements were taken at the first ‘non-zero’ volume, and at the 
volume at which developed pressure was greatest, or the maximum volume achieved 
before the onset of arrhythmia. The mandrel volume of 3.5ml was added to the balloon 
volume, and ml/g heart weight was used to estimate LV distension for the purposes of 
comparison between hearts of differing size.  
 
Analysis of the Frank-Starling response. Using the same time points as above, we 
measured developed pressure (Pdev), defined as peak minus diastolic pressure.  
 
Inotropic response to epinephrine. Response of Pdev to epinephrine doses of 10, 33, 
100µg/L perfusate was measured at the first non-zero balloon volume in volume ramps 
at each epinephrine concentration.  
 
Analysis of +/- dP/dt. Rates of force development and relaxation were measured at the 
same time points as developed pressure. [8] We used Acknowledge software package 
to filter LV pressure waves for noise above 10hz, and to generate a derivative waveform. 
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(+) and (–) dP/dt were measured as the maximum and minimum values of the derivative 
waveform, respectively, averaged over three breaths (Fig. 28). 
 
Statistics. All data in figures is presented as means ± SDEV. Significance between 
groups was tested with paired or unpaired Student’s t-test as appropriate. Correlation 
between parameters was tested by calculating the Pearson’s correlation coefficient, and 
determining the value of p based on the sample size.  
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From Chapter 2: Right Ventricular Trabeculae Studies. 
 
Free-running, non-branching trabeculae were then carefully dissected from the right 
ventricle (Fig. 29). Average dimensions for the trabeculae were 0.55 ± 0.05 mm thick, 
0.44 ± 0.03 mm wide, 1.95 ± 0.14 mm long. Dissected trabeculae were immediately 
placed in cold Krebs–Henseleit buffer (KHB) solution with 20mmol/L of 2,3-butanedione 
monoxime (BDM). and 0.25mmol/L CaCl2 added to it. KHB solution used for all 
trabeculae experiments contained (mmol/L): glucose (12.5), KCL (5.4), lactic acid (1.0), 
MgSO4 (1.2), NaCl (130.0), NaH2PO4 (1.2), NaHCO3 (25.0) and Na-pyruvate (2.0). 
Following dissection, trabeculae dimensions were measured and recorded. 
Individual trabeculae were then placed in a custom designed, recirculating isometric 
muscle bath chamber (Scientific Instruments, Heidelberg, Germany) by mounting them 
in a slackened position between 2 hook shaped wires, with one wire extending from a 
force transducer and the other wire extending from a microdisplacement device. 
Experimental solution was then changed to a BDM-free KHB solution that had 
1.75mmol/L CaCl2 added to it. Trabeculae were stimulated continuously with 3.0ms 
Figure 29.  Right ventricular cardiac trabeculae in situ (a) and mounted in tissue bath between a 
motor (green arrow) and a force transducer (orange arrow).  Scale bar equals 1cm. 
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assymetric pulses at a rate of 1.0Hz. Pulses were set to a voltage that was 20% above 
threshold (typically 3.0-7.0V). Experimental solution was maintained at 37°C and 
continuously bubbled with a gas mixture of 95% O2 and 5% CO2 to maintain a pH of 7.4. 
Trabeculae were then left at a low preload for 1 hour to allow the muscle to equilibrate. 
Following equilibration period, L0 (the length at which and active developed force can 
first be identified) and Lmax (the length at which maximal developed force occurs) were 
determined by methods previously described methods (Rossman E, et al., 2004).  
 
Length-Tension Experimental Design. Following determination of L0 and Lmax, contractile 
parameters were assessed at 5 muscle lengths. Muscle lengths used in this study were 
100%, 80%, 60%, 40%, and 20% of (Lmax-L0 ). Recordings of contractile parameters at 
each of these lengths were done after a 15min equilibration period to allow the 
contractions to reach a steady state. All contractile parameters for the length-tension 
experiments were assessed at a stimulation rate of 1.0Hz, and a bath calcium 
concentration of 1.75mmol/L. 
 
Post-Rest Experimental Design. Post rest experiments were done at 100%, 80%, 60%, 
40%, and 20% of (Lmax-L0 ). Once steady state contractions at a stimulation rate of 1.0Hz 
were achieved, the stimulator was turned off for a specific rest interval. Following the 
rest interval, the stimulator was turned back on at a pacing rate of 1.0Hz. The developed 
force for the contraction prior to the rest interval and the contraction immediately 
following the rest interval were recorded. The contraction following the rest interval was 
then compared to the contraction immediately prior to the rest interval. All experiments 
were done looking at rest intervals of 5, 15, 30, 60, &120 seconds.  
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Force-Frequency Experimental Design. Steady state contractile parameters were 
recorded at stimulation frequencies of 0.5, 1.0, 1.5, 2.0, and 2.5 HZ. All contractile 
parameters were assessed at 80%Lmax and a bath calcium concentration of 1.75mmol/L.  
 
Extracellular Calcium & Isoproterenol Experimental Design. Steady state contractile 
parameters were recorded at various extracellular calcium concentrations. Calcium 
concentrations used in this study were 1.0, 1.5, 1.75, 2.0, and 2.5 mmol/L. Experimental 
solution was then washed out and BDM-free KHB containing 1.75mmol/L CaCl2 was 
added to the muscle bath again. Once steady-state contractions were achieved, 
baseline contractile parameters and contractile parameters following 1.0µmol/L of 
isoproterenol were assessed. All contractile parameters were assessed at 80% Lmax and 
a stimulation rate of 1.0Hz.  
 
 
 
95 
 
 
Bibliography 
 
Alexakis, C., Partridge, T. & Bou-Gharios, G. 2007, "Implication of the satellite cell in 
dystrophic muscle fibrosis: a self-perpetuating mechanism of collagen 
overproduction", American journal of physiology.Cell physiology, vol. 293, no. 2, pp. 
C661-9. 
Aliverti, A., Cala, S.J., Duranti, R., Ferrigno, G., Kenyon, C.M., Pedotti, A., Scano, G., 
Sliwinski, P., Macklem, P.T. & Yan, S. 1997, "Human respiratory muscle actions and 
control during exercise", Journal of applied physiology (Bethesda, Md.: 1985), vol. 
83, no. 4, pp. 1256-1269. 
Allen, G.D. 2001, "Eccentric muscle damage: Mechanisms of early reduction of force", 
Acta Physiol Scand, vol. 171, pp. 311-319. 
ALLEN, J.E. & RODGIN, D.W. 1960, "Mental retardation in association with progressive 
dystrophy", American Journal of Diseases of Children (1960), vol. 100, pp. 208-211. 
Bachrach, E., Li, S., Perez, A.L., Schienda, J., Liadaki, K., Volinski, J., Flint, A., 
Chamberlain, J. & Kunkel, L.M. 2004, "Systemic delivery of human microdystrophin 
to regenerating mouse dystrophic muscle by muscle progenitor cells", Proceedings 
of the National Academy of Sciences of the United States of America, vol. 101, no. 
10, pp. 3581-3586. 
Baltzer, W.I., Calise, D.V., Levine, J.M., Shelton, G.D., Edwards, J.F. & Steiner, J.M. 
2007, "Dystrophin-deficient muscular dystrophy in a Weimaraner", Journal of the 
American Animal Hospital Association, vol. 43, no. 4, pp. 227-232. 
Barnabei, M.S. & Metzger, J.M. 2012, "Ex vivo stretch reveals altered mechanical 
properties of isolated dystrophin-deficient hearts", PloS one, vol. 7, no. 3, pp. 
e32880. 
Barresi, R. & Campbell, K.P. 2006, "Dystroglycan: from biosynthesis to pathogenesis of 
human disease", Journal of cell science, vol. 119, no. Pt 2, pp. 199-207. 
Barthelemy, I., Barrey, E., Aguilar, P., Uriarte, A., Le Chevoir, M., Thibaud, J.L., Voit, T., 
Blot, S. & Hogrel, J.Y. 2011, "Longitudinal ambulatory measurements of gait 
abnormality in dystrophin-deficient dogs", BMC musculoskeletal disorders, vol. 12, 
pp. 75. 
Barthelemy, I., Barrey, E., Thibaud, J.L., Uriarte, A., Voit, T., Blot, S. & Hogrel, J.Y. 
2009, "Gait analysis using accelerometry in dystrophin-deficient dogs", 
Neuromuscular disorders : NMD, vol. 19, no. 11, pp. 788-796. 
Bassett, D.I., Bryson-Richardson, R.J., Daggett, D.F., Gautier, P., Keenan, D.G. & 
Currie, P.D. 2003, "Dystrophin is required for the formation of stable muscle 
attachments in the zebrafish embryo", Development (Cambridge, England), vol. 
130, no. 23, pp. 5851-5860. 
Bell, R.M., Mocanu, M.M. & Yellon, D.M. 2011, "Retrograde heart perfusion: the 
Langendorff technique of isolated heart perfusion", Journal of Molecular and Cellular 
Cardiology, vol. 50, no. 6, pp. 940-950. 
Berntson, G.G., Cacioppo, J.T. & Quigley, K.S. 1993, "Respiratory sinus arrhythmia: 
autonomic origins, physiological mechanisms, and psychophysiological 
implications", Psychophysiology, vol. 30, no. 2, pp. 183-196. 
96 
 
Bessou, C., Giugia, J.B., Franks, C.J., Holden-Dye, L. & Segalat, L. 1998, "Mutations in 
the Caenorhabditis elegans dystrophin-like gene dys-1 lead to hyperactivity and 
suggest a link with cholinergic transmission", Neurogenetics, vol. 2, no. 1, pp. 61-72. 
Birnkrant, D.J., Bushby, K.M., Amin, R.S., Bach, J.R., Benditt, J.O., Eagle, M., Finder, 
J.D., Kalra, M.S., Kissel, J.T., Koumbourlis, A.C. & Kravitz, R.M. 2010, "The 
respiratory management of patients with duchenne muscular dystrophy: a DMD care 
considerations working group specialty article", Pediatric pulmonology, vol. 45, no. 
8, pp. 739-748. 
Bish, L.T., Sleeper, M.M., Forbes, S.C., Wang, B., Reynolds, C., Singletary, G.E., 
Trafny, D., Morine, K.J., Sanmiguel, J., Cecchini, S., Virag, T., Vulin, A., Beley, C., 
Bogan, J., Wilson, J.M., Vandenborne, K., Kornegay, J.N., Walter, G.A., Kotin, R.M., 
Garcia, L. & Sweeney, H.L. 2012, "Long-term restoration of cardiac dystrophin 
expression in golden retriever muscular dystrophy following rAAV6-mediated exon 
skipping", Molecular therapy : the journal of the American Society of Gene Therapy, 
vol. 20, no. 3, pp. 580-589. 
Border, W.A. & Noble, N.A. 1994, "Transforming growth factor beta in tissue fibrosis", 
The New England journal of medicine, vol. 331, no. 19, pp. 1286-1292. 
Brumitt, J.W., Essman, S.C., Kornegay, J.N., Graham, J.P., Weber, W.J. & Berry, C.R. 
2006, "Radiographic features of Golden Retriever muscular dystrophy", Veterinary 
radiology & ultrasound : the official journal of the American College of Veterinary 
Radiology and the International Veterinary Radiology Association, vol. 47, no. 6, pp. 
574-580. 
Bulfield, G., Siller, W.G., Wight, P.A. & Moore, K.J. 1984, "X chromosome-linked 
muscular dystrophy (mdx) in the mouse", Proceedings of the National Academy of 
Sciences of the United States of America, vol. 81, no. 4, pp. 1189-1192. 
Campbell, K.P. & Kahl, S.D. 1989, "Association of dystrophin and an integral membrane 
glycoprotein", Nature, vol. 338, no. 6212, pp. 259-262. 
Chambers, S.P., Dodd, A., Overall, R., Sirey, T., Lam, L.T., Morris, G.E. & Love, D.R. 
2001, "Dystrophin in adult zebrafish muscle", Biochemical and biophysical research 
communications, vol. 286, no. 3, pp. 478-483. 
Chenard, A.A., Becane, H.M., Tertrain, F., de Kermadec, J.M. & Weiss, Y.A. 1993, 
"Ventricular arrhythmia in Duchenne muscular dystrophy: prevalence, significance 
and prognosis", Neuromuscular disorders : NMD, vol. 3, no. 3, pp. 201-206. 
Chetboul, V., Escriou, C., Tessier, D., Richard, V., Pouchelon, J.L., Thibault, H., 
Lallemand, F., Thuillez, C., Blot, S. & Derumeaux, G. 2004, "Tissue Doppler 
imaging detects early asymptomatic myocardial abnormalities in a dog model of 
Duchenne's cardiomyopathy", European heart journal, vol. 25, no. 21, pp. 1934-
1939. 
Chetboul, V., Serres, F., Gouni, V., Tissier, R. & Pouchelon, J.L. 2007, "Radial strain and 
strain rate by two-dimensional speckle tracking echocardiography and the tissue 
velocity based technique in the dog", Journal of veterinary cardiology : the official 
journal of the European Society of Veterinary Cardiology, vol. 9, no. 2, pp. 69-81. 
Childers, M.K., Okamura, C.S., Bogan, D.J., Bogan, J.R., Petroski, G.F., McDonald, K. & 
Kornegay, J.N. 2002, "Eccentric contraction injury in dystrophic canine muscle", 
Arch Phys Med Rehabil, vol. 83, pp. 1572-1578. 
Childers, M.K., Grange, R.W. & Kornegay, J.N. 2011, "In vivo canine muscle function 
assay", Journal of visualized experiments : JoVE, vol. (50). pii: 2623. doi, no. 50, pp. 
10.3791/2623. 
97 
 
 
Childers, M.K., Okamura, C.S., Bogan, D.J., Bogan, J.R., Sullivan, M.J. & Kornegay, 
J.N. 2001, "Myofiber injury and regeneration in a canine homologue of Duchenne 
muscular dystrophy", American Journal of Physical Medicine & Rehabilitation / 
Association of Academic Physiatrists, vol. 80, no. 3, pp. 175-181. 
Claflin, D.R. & Brooks, S.V. 2007, "Direct observation of failing fibers in muscles of 
dystrophic mice provides mechanistic insight into muscular dystrophy", Am J Physiol 
Cell Physiol, vol. 294, pp. 651-658. 
Clanton, T.L. & Levine, S. 2009, "Respiratory muscle fiber remodeling in chronic 
hyperinflation: dysfunction or adaptation?", Journal of applied physiology (Bethesda, 
Md.: 1985), vol. 107, no. 1, pp. 324-335. 
Cohen, C.A., Zagelbaum, G., Gross, D., Roussos, C. & Macklem, P.T. 1982, "Clinical 
manifestations of inspiratory muscle fatigue", The American Journal of Medicine, 
vol. 73, no. 3, pp. 308-316. 
Cooper, B.J., Winand, N.J., Stedman, H., Valentine, B.A., Hoffman, E.P., Kunkel, L.M., 
Scott, M.O., Fischbeck, K.H., Kornegay, J.N. & Avery, R.J. 1988a, "The homologue 
of the Duchenne locus is defective in X-linked muscular dystrophy of dogs", Nature, 
vol. 334, no. 6178, pp. 154-156. 
Cooper, B.J., Winand, N.J., Stedman, H., Valentine, B.A., Hoffman, E.P., Kunkel, L.M., 
Scott, M.O., Fischbeck, K.H., Kornegay, J.N. & Avery, R.J. 1988b, "The homologue 
of the Duchenne locus is defective in X-linked muscular dystrophy of dogs", Nature, 
vol. 334, no. 6178, pp. 154-156. 
Cotten, J.F., Keshavaprasad, B., Laster, M.J., Eger, E.I.,2nd & Yost, C.S. 2006, "The 
ventilatory stimulant doxapram inhibits TASK tandem pore (K2P) potassium channel 
function but does not affect minimum alveolar anesthetic concentration", Anesthesia 
and Analgesia, vol. 102, no. 3, pp. 779-785. 
Cotton, S.M., Voudouris, N.J. & Greenwood, K.M. 2005, "Association between 
intellectual functioning and age in children and young adults with Duchenne 
muscular dystrophy: further results from a meta-analysis", Developmental medicine 
and child neurology, vol. 47, no. 4, pp. 257-265. 
Cozzi, F., Cerletti, M., Luvoni, G.C., Lombardo, R., Brambilla, P.G., Faverzani, S., 
Blasevich, F., Cornelio, F., Pozza, O. & Mora, M. 2001, "Development of muscle 
pathology in canine X-linked muscular dystrophy. II. Quantitative characterization of 
histopathological progression during postnatal skeletal muscle development", Acta 
Neuropathologica, vol. 101, no. 5, pp. 469-478. 
Dagan, O., Nimri, R., Katz, Y., Birk, E. & Vidne, B. 2006, "Bilateral diaphragm paralysis 
following cardiac surgery in children: 10-years' experience", Intensive care 
medicine, vol. 32, no. 8, pp. 1222-1226. 
De Bruin, P.F., Ueki, J., Bush, A., Y Manzur, A., Watson, A. & Pride, N.B. 2001, 
"Inspiratory flow reserve in boys with Duchenne muscular dystrophy", Pediatric 
pulmonology, vol. 31, no. 6, pp. 451-457. 
de Kermadec, J.M., Becane, H.M., Chenard, A., Tertrain, F. & Weiss, Y. 1994, 
"Prevalence of left ventricular systolic dysfunction in Duchenne muscular dystrophy: 
an echocardiographic study", American Heart Journal, vol. 127, no. 3, pp. 618-623. 
Deconinck, A.E., Rafael, J.A., Skinner, J.A., Brown, S.C., Potter, A.C., Metzinger, L., 
Watt, D.J., Dickson, J.G., Tinsley, J.M. & Davies, K.E. 1997, "Utrophin-dystrophin-
deficient mice as a model for Duchenne muscular dystrophy", Cell, vol. 90, no. 4, 
pp. 717-727. 
98 
 
Desjardins, P.R., Burkman, J.M., Shrager, J.B., Allmond, L.A. & Stedman, H.H. 2002, 
"Evolutionary implications of three novel members of the Human sarcomeric myosin 
heavy chain gene family", Molecular Biology and Evolution, vol. 19, no. 4, pp. 375-
393. 
Devaux, J.Y., Cabane, L., Esler, M., Flaouters, H. & Duboc, D. 1993, "Non-invasive 
evaluation of the cardiac function in golden retriever dogs by radionuclide 
angiography", Neuromuscular disorders : NMD, vol. 3, no. 5-6, pp. 429-432. 
Dodd, D.S., Brancatisano, T. & Engel, L.A. 1984, "Chest wall mechanics during exercise 
in patients with severe chronic air-flow obstruction", The American Review of 
Respiratory Disease, vol. 129, no. 1, pp. 33-38. 
Dooley, J., Gordon, K.E., Dodds, L. & MacSween, J. 2010, "Duchenne muscular 
dystrophy: a 30-year population-based incidence study", Clinical pediatrics, vol. 49, 
no. 2, pp. 177-179. 
Eagle, M., Bourke, J., Bullock, R., Gibson, M., Mehta, J., Giddings, D., Straub, V. & 
Bushby, K. 2007, "Managing Duchenne muscular dystrophy--the additive effect of 
spinal surgery and home nocturnal ventilation in improving survival", Neuromuscular 
disorders : NMD, vol. 17, no. 6, pp. 470-475. 
Elemans, C.P.H., Mead, A.F., Rome, L.C. & Goller, F. 2008, "Superfast vocal muscles 
control song production in songbirds", PLOS one, vol. 3, no. 7. 
Elemans, C.P., Mead, A.F., Jakobsen, L. & Ratcliffe, J.M. 2011, "Superfast muscles set 
maximum call rate in echolocating bats", Science (New York, N.Y.), vol. 333, no. 
6051, pp. 1885-1888. 
Ervasti, J.M. & Campbell, K.P. 1993, "A role for the dystrophin-glycoprotein complex as 
a transmembrane linker between laminin and actin", J Cell Biol, vol. 122, no. 4, pp. 
809-823. 
Ferrer, A., Wells, K.E. & Wells, D.J. 2000, "Immune responses to dystropin: implications 
for gene therapy of Duchenne muscular dystrophy", Gene therapy, vol. 7, no. 17, 
pp. 1439-1446. 
Finder, J.D., Birnkrant, D., Carl, J., Farber, H.J., Gozal, D., Iannaccone, S.T., Kovesi, T., 
Kravitz, R.M., Panitch, H., Schramm, C., Schroth, M., Sharma, G., Sievers, L., 
Silvestri, J.M., Sterni, L. & American Thoracic Society 2004, "Respiratory care of the 
patient with Duchenne muscular dystrophy: ATS consensus statement", American 
journal of respiratory and critical care medicine, vol. 170, no. 4, pp. 456-465. 
Frueh, B.R., Hayes, A., Lynch, G.S. & Williams, D.A. 1994, "Contractile properties and 
temperature sensitivity of the extraocular muscles, the levator and superior rectus, 
of the rabbit", J Physiol, vol. 475, no. 2, pp. 327-336. 
Furch, M., Geeves, M.A. & Manstein, D.J. 1998, "Modulation of actin affinity and 
actomyosin adenosine trihosphatase by charge changes in the myosin motor 
domain", Biochemistry, vol. 37, pp. 6317-6326. 
Gao, Y., Wineman, A.S. & Waas, A.M. 2008, "Mechanics of muscle injury induced by 
lengthening contractions", Annals of Biomedical Engineering, vol. 10, no. 1615, pp. 
1623. 
Gayraud, J., Ramonatxo, M., Rivier, F., Humberclaude, V., Petrof, B. & Matecki, S. 
2010, "Ventilatory parameters and maximal respiratory pressure changes with age 
in Duchenne muscular dystrophy patients", Pediatric pulmonology, vol. 45, no. 6, 
pp. 552-559. 
Geeves, M.A. & Holmes, K.C. 1999, "Structural mechanism of muscle contraction", 
Annu. Rev. Biochem., vol. 68, pp. 687-728. 
99 
 
Gelse, K., Poschl, E. & Aigner, T. 2003, "Collagens--structure, function, and 
biosynthesis", Advanced Drug Delivery Reviews, vol. 55, no. 12, pp. 1531-1546. 
Gilbert, R., Auchincloss, J.H.,Jr, Peppi, D. & Ashutosh, K. 1974, "The first few hours off a 
respirator", Chest, vol. 65, no. 2, pp. 152-157. 
Gillies, A.R. & Lieber, R.L. 2011, "Structure and function of the skeletal muscle 
extracellular matrix", Muscle & nerve, vol. 44, no. 3, pp. 318-331. 
Gillies, A.R., Smith, L.R., Lieber, R.L. & Varghese, S. 2011, "Method for decellularizing 
skeletal muscle without detergents or proteolytic enzymes", Tissue engineering.Part 
C, Methods, vol. 17, no. 4, pp. 383-389. 
Goyenvalle, A., Vulin, A., Fougerousse, F., Leturcq, F., Kaplan, J.C., Garcia, L. & Danos, 
O. 2004, "Rescue of dystrophic muscle through U7 snRNA-mediated exon 
skipping", Science (New York, N.Y.), vol. 306, no. 5702, pp. 1796-1799. 
Grady, R.M., Teng, H., Nichol, M.C., Cunningham, J.C., Wilkinson, R.S. & Sanes, J.R. 
1997, "Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a 
model for Duchenne muscular dystrophy", Cell, vol. 90, no. 4, pp. 729-738. 
Gregorevic, P., Allen, J.M., Minami, E., Blankinship, M.J., Haraguchi, M., Meuse, L., 
Finn, E., Adams, M.E., Froehner, S.C., Murry, C.E. & Chamberlain, J.S. 2006, 
"rAAV6-microdystrophin preserves muscle function and extends lifespan in severely 
dystrophic mice", Nature medicine, vol. 12, no. 7, pp. 787-789. 
Gregorevic, P., Blankinship, M.J., Allen, J.M., Crawford, R.W., Meuse, L., Miller, D.G., 
Russell, D.W. & Chamberlain, J.S. 2004, "Systemic delivery of genes to striated 
muscles using adeno-associated viral vectors", Nature medicine, vol. 10, no. 8, pp. 
828-834. 
Gregorevic, P., Blankinship, M.J. & Chamberlain, J.S. 2004, "Viral vectors for gene 
transfer to striated muscle", Current opinion in molecular therapeutics, vol. 6, no. 5, 
pp. 491-498. 
Grimby, G., Goldman, M. & Mead, J. 1976, "Respiratory muscle action inferred from rib 
cage and abdominal V-P partitioning", Journal of applied physiology, vol. 41, no. 5 
Pt. 1, pp. 739-751. 
Harper, S.Q., Hauser, M.A., DelloRusso, C., Duan, D., Crawford, R.W., Phelps, S.F., 
Harper, H.A., Robinson, A.S., Engelhardt, J.F., Brooks, S.V. & Chamberlain, J.S. 
2002, "Modular flexibility of dystrophin: implications for gene therapy of Duchenne 
muscular dystrophy", Nature medicine, vol. 8, no. 3, pp. 253-261. 
Henneman, E., Somjen, G. & Carpenter, D.O. 1965, "Excitability and inhibitability of 
motoneurons of different sizes", Journal of neurophysiology, vol. 28, no. 3, pp. 599-
620. 
Hoffman, E.P., Brown, R.H. & Kunkel, L.M. 1987, "Dystrophin: the protein product of the 
Duchene muscular dystrophy locus. 1987", Biotechnology (Reading, Mass.), vol. 24, 
pp. 457-466. 
Hoh, J.F.Y. 2002, "'Superfast' or masticatory myosin and the evolution of jaw-closing 
muscles of vertebrates", The Journal of Experimental Biology, vol. 205, pp. 2203-
2210. 
Hoh, J.F.Y., Li, Z., Qin, H., Hsu, M.K.H. & Rossmanith, G.H. 2007, "Cross-bridge kinetics 
of fast and slow fibers of cat jaw and limb muscles: Correlations with myosin subunit 
composition", J Muscle Res Cell Motil, vol. 28, pp. 329-341. 
Huxley, A.F. 1957, "Muscle structure and theories of contraction", Prog Biophys Biophys 
Chem, vol. 7, pp. 255-318. 
Jones, B.R., Brennan, S., Mooney, C.T., Callanan, J.J., McAllister, H., Guo, L.T., Martin, 
P.T., Engvall, E. & Shelton, G.D. 2004, "Muscular dystrophy with truncated 
100 
 
dystrophin in a family of Japanese Spitz dogs", Journal of the neurological sciences, 
vol. 217, no. 2, pp. 143-149. 
Kaminski, H.J., al-Hakim, M., Leigh, R.J., Katirji, M.B. & Ruff, R.L. 1992, "Extraocular 
muscles are spared in advanced Duchenne dystrophy", Annals of Neurology, vol. 
32, no. 4, pp. 586-588. 
Kanagawa, M. & Toda, T. 2006, "The genetic and molecular basis of muscular 
dystrophy: roles of cell-matrix linkage in the pathogenesis", Journal of human 
genetics, vol. 51, no. 11, pp. 915-926. 
Karpati, G. & Carpenter, S. 1986, "Small-caliber skeletal muscle fibers do not suffer 
deleterious consequences of dystrophic gene expression", American Journal of 
Medical Genetics, vol. 25, no. 4, pp. 653-658. 
Kellman, P., Hernando, D., Shah, S., Hoyt, R.F.J., Kotin, R., Keene, B.W., Kornegay, 
J.N., Aletras, A.H. & Arai, A.E. 2009, "Myocardial fibro- fatty infiltration in duchenne 
muscular dystrophy canine model detected using multi-echo Dixon method of water 
and fat separation imaging.", ISMRM, . 
Khurana, T.S., Prendergast, R.A., Alameddine, H.S., Tome, F.M., Fardeau, M., Arahata, 
K., Sugita, H. & Kunkel, L.M. 1995, "Absence of extraocular muscle pathology in 
Duchenne's muscular dystrophy: role for calcium homeostasis in extraocular muscle 
sparing", The Journal of experimental medicine, vol. 182, no. 2, pp. 467-475. 
Kobayashi, M., Nakamura, A., Hasegawa, D., Fujita, M., Orima, H. & Takeda, S. 2009, 
"Evaluation of dystrophic dog pathology by fat-suppressed T2-weighted imaging", 
Muscle & nerve, vol. 40, no. 5, pp. 815-826. 
Koenig, M., Beggs, A.H., Moyer, M., Scherpf, S., Heindrich, K., Bettecken, T., Meng, G., 
Muller, C.R., Lindlof, M. & Kaariainen, H. 1989, "The molecular basis for Duchenne 
versus Becker muscular dystrophy: correlation of severity with type of deletion", 
American Journal of Human Genetics, vol. 45, no. 4, pp. 498-506. 
Kornegay, J.N., Bogan, D.J., Bogan, J.R., Childers, M.K., Cundiff, D.D., Petroski, G.F. & 
Schueler, R.O. 1999, "Contraction force generated by tarsal joint flexion and 
extension in dogs with golden retriever muscular dystrophy", Journal of the 
Neurological Sciences, vol. 166, pp. 115-121. 
Kornegay, J.N., Bogan, J.R., Bogan, D.J., Childers, M.K., Li, J., Nghiem, P., Detwiler, 
D.A., Larsen, C.A., Grange, R.W., Bhavaraju-Sanka, R.K., Tou, S., Keene, B.P., 
Howard, J.F.,Jr, Wang, J., Fan, Z., Schatzberg, S.J., Styner, M.A., Flanigan, K.M., 
Xiao, X. & Hoffman, E.P. 2012, "Canine models of Duchenne muscular dystrophy 
and their use in therapeutic strategies", Mammalian genome : official journal of the 
International Mammalian Genome Society, vol. 23, no. 1-2, pp. 85-108. 
Kornegay, J.N., Cundiff, D.D., Bogan, D.J., Bogan, J.R. & Okamura, C.S. 2003, "The 
cranial sartorius muscle undergoes true hypertrophy in dogs with golden retriever 
muscular dystrophy", Neuromuscular disorders : NMD, vol. 13, no. 6, pp. 493-500. 
Kornegay, J.N., Sharp, N.J., Bogan, D.J., Van Camp, S.D., Metcalf, J.R. & Schueler, 
R.O. 1994a, "Contraction tension and kinetics of the peroneus longus muscle in 
golden retriever muscular dystrophy", Journal of the neurological sciences, vol. 123, 
no. 1-2, pp. 100-107. 
Kornegay, J.N., Sharp, N.J., Schueler, R.O. & Betts, C.W. 1994b, "Tarsal joint 
contracture in dogs with golden retriever muscular dystrophy", Laboratory animal 
science, vol. 44, no. 4, pp. 331-333. 
Kornegay, J.N., Tuler, S.M., Miller, D.M. & Levesque, D.C. 1988, "Muscular dystrophy in 
a litter of golden retriever dogs", Muscle & nerve, vol. 11, no. 10, pp. 1056-1064. 
101 
 
Kurzawa-Goertz, S.E., Perreault-Micale, C.L., Trybus, K.M., Szent-Gyorgyi, A.G. & 
Geeves, M.A. 1998, "Loop I can modulate ADP affinity, ATPase activity, and motility 
of different scallop myosins. Transient kinetic analysis of S1 isoforms", 
Biochemistry, vol. 37, pp. 7517-7525. 
Langendorff, O. 1895, "Untersuchungen am überlebenden Säugethierherzen", 
Pflüger, Archiv für die Gesammte Physiologie des Menschen und der Thiere, vol. 
61, no. 6, pp. 291-332. 
Lanza, G.A., Dello Russo, A., Giglio, V., De Luca, L., Messano, L., Santini, C., Ricci, E., 
Damiani, A., Fumagalli, G., De Martino, G., Mangiola, F. & Bellocci, F. 2001, 
"Impairment of cardiac autonomic function in patients with Duchenne muscular 
dystrophy: relationship to myocardial and respiratory function", American Heart 
Journal, vol. 141, no. 5, pp. 808-812. 
Leask, A. 2007, "TGFbeta, cardiac fibroblasts, and the fibrotic response", Cardiovascular 
research, vol. 74, no. 2, pp. 207-212. 
Lehti, T.M., Kalliokoski, R. & Komulainen, J. 2007, "Repeated bout effect on the 
cytoskeletal proteins titin, desmin, and dystrophin in rat skeletal muscle", Journal of 
Muscle Research and Cell Motility, vol. 28, no. 1. 
Levine, S., Gillen, M., Weiser, P., Feiss, G., Goldman, M. & Henson, D. 1988, 
"Inspiratory pressure generation: comparison of subjects with COPD and age-
matched normals", Journal of applied physiology (Bethesda, Md.: 1985), vol. 65, no. 
2, pp. 888-899. 
Li, S., Kimura, E., Fall, B.M., Reyes, M., Angello, J.C., Welikson, R., Hauschka, S.D. & 
Chamberlain, J.S. 2005, "Stable transduction of myogenic cells with lentiviral 
vectors expressing a minidystrophin", Gene therapy, vol. 12, no. 14, pp. 1099-1108. 
Linari, M., Bottinelli, R., Pellegrino, M.A., Reconditi, M., Reggiani, C. & Lombardi, V. 
2004, "The mechanism of the force response to stretch in human skinned muscle 
fibers with different myosin isoforms", J Physiol, vol. 554, no. 2, pp. 335-352. 
Lo Mauro, A., D'Angelo, M.G., Romei, M., Motta, F., Colombo, D., Comi, G.P., Pedotti, 
A., Marchi, E., Turconi, A.C., Bresolin, N. & Aliverti, A. 2010, "Abdominal volume 
contribution to tidal volume as an early indicator of respiratory impairment in 
Duchenne muscular dystrophy", The European respiratory journal : official journal of 
the European Society for Clinical Respiratory Physiology, vol. 35, no. 5, pp. 1118-
1125. 
Malik, V., Rodino-Klapac, L.R., Viollet, L., Wall, C., King, W., Al-Dahhak, R., Lewis, S., 
Shilling, C.J., Kota, J., Serrano-Munuera, C., Hayes, J., Mahan, J.D., Campbell, 
K.J., Banwell, B., Dasouki, M., Watts, V., Sivakumar, K., Bien-Willner, R., Flanigan, 
K.M., Sahenk, Z., Barohn, R.J., Walker, C.M. & Mendell, J.R. 2010, "Gentamicin-
induced readthrough of stop codons in Duchenne muscular dystrophy", Annals of 
Neurology, vol. 67, no. 6, pp. 771-780. 
Marsh, A.P., Eggebeen, J.D., Kornegay, J.N., Markert, C.D. & Childers, M.K. 2010, 
"Kinematics of gait in golden retriever muscular dystrophy", Neuromuscular 
disorders : NMD, vol. 20, no. 1, pp. 16-20. 
McDonald, C.M., Abresch, R.T., Carter, G.T., Fowler, W.M.,Jr, Johnson, E.R., Kilmer, 
D.D. & Sigford, B.J. 1995, "Profiles of neuromuscular diseases. Duchenne muscular 
dystrophy", American Journal of Physical Medicine & Rehabilitation / Association of 
Academic Physiatrists, vol. 74, no. 5 Suppl, pp. S70-92. 
Megeney, L.A., Kablar, B., Perry, R.L., Ying, C., May, L. & Rudnicki, M.A. 1999, "Severe 
cardiomyopathy in mice lacking dystrophin and MyoD", Proceedings of the National 
Academy of Sciences of the United States of America, vol. 96, no. 1, pp. 220-225. 
102 
 
Menke, A. & Jockusch, H. 1991, "Decreased osmotic stability of dystrophin-less muscle 
cells from the mdx mouse", Nature, vol. 349, no. 6304, pp. 69-71. 
Meyer, G.A. & Lieber, R.L. 2011, "Elucidation of extracellular matrix mechanics from 
muscle fibers and fiber bundles", Journal of Biomechanics, vol. 44, no. 4, pp. 771-
773. 
MILIC-EMILI, J., MEAD, J., TURNER, J.M. & GLAUSER, E.M. 1964, "Improved 
Technique for Estimating Pleural Pressure from Esophageal Balloons", Journal of 
applied physiology, vol. 19, pp. 207-211. 
Mingozzi, F., Maus, M.V., Hui, D.J., Sabatino, D.E., Murphy, S.L., Rasko, J.E., Ragni, 
M.V., Manno, C.S., Sommer, J., Jiang, H., Pierce, G.F., Ertl, H.C. & High, K.A. 
2007, "CD8(+) T-cell responses to adeno-associated virus capsid in humans", 
Nature medicine, vol. 13, no. 4, pp. 419-422. 
Miura, P. & Jasmin, B.J. 2006, "Utrophin upregulation for treating Duchenne or Becker 
muscular dystrophy: how close are we?", Trends in molecular medicine, vol. 12, no. 
3, pp. 122-129. 
Moise, N.S., Valentine, B.A., Brown, C.A., Erb, H.N., Beck, K.A., Cooper, B.J. & Gilmour, 
R.F. 1991, "Duchenne's cardiomyopathy in a canine model: electrocardiographic 
and echocardiographic studies", Journal of the American College of Cardiology, vol. 
17, no. 3, pp. 812-820. 
Monaco, A.P. & Kunkel, L.M. 1988, "Cloning of the Duchenne/Becker muscular 
dystrophy locus", Advances in Human Genetics, vol. 17, pp. 61-98. 
Monaco, A.P., Neve, R.L., Colletti-Feener, C., Bertelson, C.J., Kurnit, D.M. & Kunkel, 
L.M. 1986, "Isolation of candidate cDNAs for portions of the Duchenne muscular 
dystrophy gene", Nature, vol. 323, no. 6089, pp. 646-650. 
Morel-Verdebout, C., Botteron, S. & Kiliaridis, S. 2007, "Dentofacial characteristics of 
growing patients with Duchenne muscular dystrophy: a morphological study", 
European journal of orthodontics, vol. 29, no. 5, pp. 500-507. 
Moxley, R.T.,3rd, Pandya, S., Ciafaloni, E., Fox, D.J. & Campbell, K. 2010, "Change in 
natural history of Duchenne muscular dystrophy with long-term corticosteroid 
treatment: implications for management", Journal of child neurology, vol. 25, no. 9, 
pp. 1116-1129. 
Murphy, D.J., Renninger, J.P. & Schramek, D. 2010, "Respiratory inductive 
plethysmography as a method for measuring ventilatory parameters in conscious, 
non-restrained dogs", Journal of pharmacological and toxicological methods, vol. 
62, no. 1, pp. 47-53. 
Neely, J.R., Liebermeister, H., Battersby, E.J. & Morgan, H.E. 1967, "Effect of pressure 
development on oxygen consumption by isolated rat heart", The American Journal 
of Physiology, vol. 212, no. 4, pp. 804-814. 
Neuman, S., Kaban, A., Volk, T., Yaffe, D. & Nudel, U. 2001, "The dystrophin / utrophin 
homologues in Drosophila and in sea urchin", Gene, vol. 263, no. 1-2, pp. 17-29. 
Nguyen, F., Cherel, Y., Guigand, L., Goubault-Leroux, I. & Wyers, M. 2002, "Muscle 
lesions associated with dystrophin deficiency in neonatal golden retriever puppies", 
Journal of comparative pathology, vol. 126, no. 2-3, pp. 100-108. 
Nicot, F., Hart, N., Forin, V., Boule, M., Clement, A., Polkey, M.I., Lofaso, F. & Fauroux, 
B. 2006, "Respiratory muscle testing: a valuable tool for children with 
neuromuscular disorders", American journal of respiratory and critical care 
medicine, vol. 174, no. 1, pp. 67-74. 
Odom, G.L., Gregorevic, P., Allen, J.M., Finn, E. & Chamberlain, J.S. 2008, 
"Microutrophin delivery through rAAV6 increases lifespan and improves muscle 
103 
 
function in dystrophic dystrophin/utrophin-deficient mice", Molecular therapy : the 
journal of the American Society of Gene Therapy, vol. 16, no. 9, pp. 1539-1545. 
Patterson, S.W. & Starling, E.H. 1914, "On the mechanical factors which determine the 
output of the ventricles", The Journal of physiology, vol. 48, no. 5, pp. 357-379. 
Petrof, B.J., Shrager, J.B., Stedman, H.H., Kely, A.M. & Sweeney, H.L. 1993a, 
"Dystrophin protects the sarcolemma from stresses develpoed during muscle 
contraction", Proc Natl Acad Sci U S A, vol. 90, no. 8, pp. 3710-3714. 
Petrof, B.J., Stedman, H.H., Shrager, J.B., Eby, J., Sweeney, H.L. & Kelly, A.M. 1993b, 
"Adaptations in myosin heavy chain expression and contractile function in 
dystrophic mouse diaphragm", The American Journal of Physiology, vol. 265, no. 3 
Pt 1, pp. C834-41. 
Qin, H., Hsu, M.K.H., Morris, B.J. & Hoh, J.F.Y. 2002, "A distinct subclass of mammalian 
striated myosins: Structure and molecular evolution of "superfast" or masticatory 
myosin heavy chain", Journal of molecular evolution, vol. 55, pp. 544-552. 
Quaile, M.P., Rossman, E.I., Berretta, R.M., Bratinov, G., Kubo, H., Houser, S.R. & 
Margulies, K.B. 2007, "Reduced sarcoplasmic reticulum Ca(2+) load mediates 
impaired contractile reserve in right ventricular pressure overload", Journal of 
Molecular and Cellular Cardiology, vol. 43, no. 5, pp. 552-563. 
Rasgado-Flores, H., Taylor, S.R., Pena-Rasgado, C., Orgel, J. & Gonzalez-Serratos, H. 
"Muscle contraction and cell volume changes in skeletal muscle", Journal of Muscle 
Research and Cell Motility, vol. 25, pp. 593-597. 
Rohman, M.S., Emoto, N., Takeshima, Y., Yokoyama, M. & Matsuo, M. 2003, 
"Decreased mAKAP, ryanodine receptor, and SERCA2a gene expression in mdx 
hearts", Biochemical and biophysical research communications, vol. 310, no. 1, pp. 
228-235. 
Rome, L.C., Cook, C., Syme, D.A., Connaughton, M.A., Ashley-Ross, M., Klimov, A., 
Tikunov, B. & Goldman, Y.E. 1999, "Trading force for speed: Why superfast 
crossbridge kinetics leads to superlow forces", Proceedings of the National 
Academy of Sciences, vol. 96, pp. 5826-5831. 
Rome, L.C., Loughna, P.T. & Goldspink, G. 1984, "Muscle fiber activity in carp as a 
function of swimming speed and muscle temperature", The American Journal of 
Physiology, vol. 247, no. 2 Pt 2, pp. R272-9. 
Romei, M., D'Angelo, M.G., LoMauro, A., Gandossini, S., Bonato, S., Brighina, E., 
Marchi, E., Comi, G.P., Turconi, A.C., Pedotti, A., Bresolin, N. & Aliverti, A. 2012, 
"Low abdominal contribution to breathing as daytime predictor of nocturnal 
desaturation in adolescents and young adults with Duchenne Muscular Dystrophy", 
Respiratory medicine, vol. 106, no. 2, pp. 276-283. 
Romfh, A. & McNally, E.M. 2010, "Cardiac assessment in duchenne and becker 
muscular dystrophies", Current heart failure reports, vol. 7, no. 4, pp. 212-218. 
Rouger, K., Larcher, T., Dubreil, L., Deschamps, J.Y., Le Guiner, C., Jouvion, G., 
Delorme, B., Lieubeau, B., Carlus, M., Fornasari, B., Theret, M., Orlando, P., 
Ledevin, M., Zuber, C., Leroux, I., Deleau, S., Guigand, L., Testault, I., Le Rumeur, 
E., Fiszman, M. & Cherel, Y. 2011, "Systemic delivery of allogenic muscle stem 
cells induces long-term muscle repair and clinical efficacy in duchenne muscular 
dystrophy dogs", The American journal of pathology, vol. 179, no. 5, pp. 2501-2518. 
Rybakova, I.N., Patel, J.R. & Ervasti, J.M. 2000, "The dystrophin complex forms a 
mechanically strong link between the sarcolemma and costameric actin", The 
Journal of cell biology, vol. 150, no. 5, pp. 1209-1214. 
104 
 
Sacco, A., Mourkioti, F., Tran, R., Choi, J., Llewellyn, M., Kraft, P., Shkreli, M., Delp, S., 
Pomerantz, J.H., Artandi, S.E. & Blau, H.M. 2010, "Short telomeres and stem cell 
exhaustion model Duchenne muscular dystrophy in mdx/mTR mice", Cell, vol. 143, 
no. 7, pp. 1059-1071. 
105 
 
 
Sackner, M.A., Watson, H., Belsito, A.S., Feinerman, D., Suarez, M., Gonzalez, G., 
Bizousky, F. & Krieger, B. 1989, "Calibration of respiratory inductive 
plethysmograph during natural breathing", Journal of applied physiology (Bethesda, 
Md.: 1985), vol. 66, no. 1, pp. 410-420. 
Sakamoto, M., Yuasa, K., Yoshimura, M., Yokota, T., Ikemoto, T., Suzuki, M., Dickson, 
G., Miyagoe-Suzuki, Y. & Takeda, S. 2002, "Micro-dystrophin cDNA ameliorates 
dystrophic phenotypes when introduced into mdx mice as a transgene", Biochemical 
and biophysical research communications, vol. 293, no. 4, pp. 1265-1272. 
Sampaolesi, M., Blot, S., D'Antona, G., Granger, N., Tonlorenzi, R., Innocenzi, A., 
Mognol, P., Thibaud, J.L., Galvez, B.G., Barthelemy, I., Perani, L., Mantero, S., 
Guttinger, M., Pansarasa, O., Rinaldi, C., Cusella De Angelis, M.G., Torrente, Y., 
Bordignon, C., Bottinelli, R. & Cossu, G. 2006, "Mesoangioblast stem cells 
ameliorate muscle function in dystrophic dogs", Nature, vol. 444, no. 7119, pp. 574-
579. 
Sarma, S., Li, N., van Oort, R.J., Reynolds, C., Skapura, D.G. & Wehrens, X.H. 2010, 
"Genetic inhibition of PKA phosphorylation of RyR2 prevents dystrophic 
cardiomyopathy", Proceedings of the National Academy of Sciences of the United 
States of America, vol. 107, no. 29, pp. 13165-13170. 
Schatzberg, S.J., Olby, N.J., Breen, M., Anderson, L.V., Langford, C.F., Dickens, H.F., 
Wilton, S.D., Zeiss, C.J., Binns, M.M., Kornegay, J.N., Morris, G.E. & Sharp, N.J. 
1999, "Molecular analysis of a spontaneous dystrophin 'knockout' dog", 
Neuromuscular disorders : NMD, vol. 9, no. 5, pp. 289-295. 
Schultz, B.R. & Chamberlain, J.S. 2008, "Recombinant adeno-associated virus 
transduction and integration", Molecular therapy : the journal of the American 
Society of Gene Therapy, vol. 16, no. 7, pp. 1189-1199. 
Schwartz, M.Z. & Filler, R.M. 1978, "Plication of the diaphragm for symptomatic phrenic 
nerve paralysis", Journal of pediatric surgery, vol. 13, no. 3, pp. 259-263. 
Sharp, N.J., Kornegay, J.N., Van Camp, S.D., Herbstreith, M.H., Secore, S.L., Kettle, S., 
Hung, W.Y., Constantinou, C.D., Dykstra, M.J. & Roses, A.D. 1992, "An error in 
dystrophin mRNA processing in golden retriever muscular dystrophy, an animal 
homologue of Duchenne muscular dystrophy", Genomics, vol. 13, no. 1, pp. 115-
121. 
Shcherbata, H.R., Yatsenko, A.S., Patterson, L., Sood, V.D., Nudel, U., Yaffe, D., Baker, 
D. & Ruohola-Baker, H. 2007, "Dissecting muscle and neuronal disorders in a 
Drosophila model of muscular dystrophy", The EMBO journal, vol. 26, no. 2, pp. 
481-493. 
Shimatsu, Y., Yoshimura, M., Yuasa, K., Urasawa, N., Tomohiro, M., Nakura, M., 
Tanigawa, M., Nakamura, A. & Takeda, S. 2005, "Major clinical and 
histopathological characteristics of canine X-linked muscular dystrophy in Japan, 
CXMDJ", Acta myologica : myopathies and cardiomyopathies : official journal of the 
Mediterranean Society of Myology / edited by the Gaetano Conte Academy for the 
study of striated muscle diseases, vol. 24, no. 2, pp. 145-154. 
Sicinski, P., Geng, Y., Ryder-Cook, A.S., Barnard, E.A., Darlison, M.G. & Barnard, P.J. 
1989, "The molecular basis of muscular dystrophy in the mdx mouse: a point 
mutation", Science (New York, N.Y.), vol. 244, no. 4912, pp. 1578-1580. 
106 
 
 
Smith, B.F., Yue, Y., Woods, P.R., Kornegay, J.N., Shin, J.H., Williams, R.R. & Duan, D. 
2011, "An intronic LINE-1 element insertion in the dystrophin gene aborts dystrophin 
expression and results in Duchenne-like muscular dystrophy in the corgi breed", 
Laboratory investigation; a journal of technical methods and pathology, vol. 91, no. 
2, pp. 216-231. 
Smith, P.E., Edwards, R.H. & Calverley, P.M. 1989, "Ventilation and breathing pattern 
during sleep in Duchenne muscular dystrophy", Chest, vol. 96, no. 6, pp. 1346-
1351. 
Stedman, H.H., Kozyak, B.W., Nelson, A., Thesier, D.M., Su, L.T., Low, D.L., Bridges, 
C.R., Shrager, J.B., Minugh-Purvis, N. & Mitchell, M.A. 2004, "Myosin gene 
mutation correlates with anatomical changes in the human lineage", Nature, vol. 
428, pp. 415-418. 
Stedman, H.H., Sweeney, H.L., Shrager, J.B., Maguire, H.C., Panettieri, R.A., Petrof, B., 
Narusawa, M., Leferovich, J.M., Sladky, J.T. & Kelly, A.M. 1991, "The mdx mouse 
diaphragm reproduces the degenerative changes of Duchenne muscular 
dystrophy", Nature, vol. 352, no. 6335, pp. 536-539. 
Su, J.B., Cazorla, O., Blot, S., Blanchard-Gutton, N., Ait Mou, Y., Barthelemy, I., Sambin, 
L., Sampedrano, C.C., Gouni, V., Unterfinger, Y., Aguilar, P., Thibaud, J.L., Bize, A., 
Pouchelon, J.L., Dabire, H., Ghaleh, B., Berdeaux, A., Chetboul, V., Lacampagne, 
A. & Hittinger, L. 2012, "Bradykinin restores left ventricular function, sarcomeric 
protein phosphorylation, and e/nNOS levels in dogs with Duchenne muscular 
dystrophy cardiomyopathy", Cardiovascular research, vol. 95, no. 1, pp. 86-96. 
Suarez, R.K., Darveau, C.A. & Childress, J.J. 2004, "Metabolic scaling: a many-
splendoured thing", Comparative biochemistry and physiology.Part B, Biochemistry 
& molecular biology, vol. 139, no. 3, pp. 531-541. 
Takano, H., Fujii, Y., Yugeta, N., Takeda, S. & Wakao, Y. 2011, "Assessment of left 
ventricular regional function in affected and carrier dogs with Duchenne muscular 
dystrophy using speckle tracking echocardiography", BMC cardiovascular disorders, 
vol. 11, pp. 23. 
Takeda, S., Nakahara, K., Fujii, Y., Matsumura, A., Minami, M. & Matsuda, H. 1995, 
"Effects of diaphragmatic plication on respiratory mechanics in dogs with unilateral 
and bilateral phrenic nerve paralyses", Chest, vol. 107, no. 3, pp. 798-804. 
Tegeler, C.J., Grange, R.W., Bogan, D.J., Markert, C.D., Case, D., Kornegay, J.N. & 
Childers, M.K. 2010, "Eccentric contractions induce rapid isometric torque drop in 
dystrophin-deficient dogs", Muscle & nerve, vol. 42, no. 1, pp. 130-132. 
Thibaud, J.L., Monnet, A., Bertoldi, D., Barthelemy, I., Blot, S. & Carlier, P.G. 2007, 
"Characterization of dystrophic muscle in golden retriever muscular dystrophy dogs 
by nuclear magnetic resonance imaging", Neuromuscular disorders : NMD, vol. 17, 
no. 7, pp. 575-584. 
Toniolo, L., Cancellara, P., Maccatrozzo, L., Patruno, M., Mascarello, F. & Regginani, C. 
2008, "Masticatory myosin unveiled: first determination of contractile parameters of 
muscle fibers from carnivore jaw muscles", AJP, . 
Townsend, D., Blankinship, M.J., Allen, J.M., Gregorevic, P., Chamberlain, J.S. & 
Metzger, J.M. 2007, "Systemic administration of micro-dystrophin restores cardiac 
geometry and prevents dobutamine-induced cardiac pump failure", Molecular 
therapy : the journal of the American Society of Gene Therapy, vol. 15, no. 6, pp. 
1086-1092. 
107 
 
Townsend, D., Turner, I., Yasuda, S., Martindale, J., Davis, J., Shillingford, M., 
Kornegay, J.N. & Metzger, J.M. 2010, "Chronic administration of membrane sealant 
prevents severe cardiac injury and ventricular dilatation in dystrophic dogs", The 
Journal of clinical investigation, vol. 120, no. 4, pp. 1140-1150. 
Townsend, D., Yasuda, S., Li, S., Chamberlain, J.S. & Metzger, J.M. 2008, "Emergent 
dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle", 
Molecular therapy : the journal of the American Society of Gene Therapy, vol. 16, 
no. 5, pp. 832-835. 
Triposkiadis, F., Karayannis, G., Giamouzis, G., Skoularigis, J., Louridas, G. & Butler, J. 
2009, "The sympathetic nervous system in heart failure physiology, 
pathophysiology, and clinical implications", Journal of the American College of 
Cardiology, vol. 54, no. 19, pp. 1747-1762. 
Ullrich, N.D., Fanchaouy, M., Gusev, K., Shirokova, N. & Niggli, E. 2009, 
"Hypersensitivity of excitation-contraction coupling in dystrophic cardiomyocytes", 
American journal of physiology.Heart and circulatory physiology, vol. 297, no. 6, pp. 
H1992-2003. 
Uyeda, T.P.Q., Ruppel, K.M. & Spudich, J.A. 1994, "Enzymatic activities correlate with 
chimaeric substitutions at the actin-binding face of myosin", Nature, vol. 368, pp. 
567-569. 
Valentine, B.A., Cummings, J.F. & Cooper, B.J. 1989, "Development of Duchenne-type 
cardiomyopathy. Morphologic studies in a canine model", The American journal of 
pathology, vol. 135, no. 4, pp. 671-678. 
Wagner, K.R., McPherron, A.C., Winik, N. & Lee, S.J. 2002, "Loss of myostatin 
attenuates severity of muscular dystrophy in mdx mice", Annals of Neurology, vol. 
52, no. 6, pp. 832-836. 
Waite, A., Tinsley, C.L., Locke, M. & Blake, D.J. 2009, "The neurobiology of the 
dystrophin-associated glycoprotein complex", Annals of Medicine, vol. 41, no. 5, pp. 
344-359. 
Walmsley, G.L., Arechavala-Gomeza, V., Fernandez-Fuente, M., Burke, M.M., Nagel, 
N., Holder, A., Stanley, R., Chandler, K., Marks, S.L., Muntoni, F., Shelton, G.D. & 
Piercy, R.J. 2010, "A duchenne muscular dystrophy gene hot spot mutation in 
dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping", 
PloS one, vol. 5, no. 1, pp. e8647. 
Wang, B., Li, J. & Xiao, X. 2000, "Adeno-associated virus vector carrying human 
minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse 
model", Proceedings of the National Academy of Sciences of the United States of 
America, vol. 97, no. 25, pp. 13714-13719. 
Wang, Z., Kuhr, C.S., Allen, J.M., Blankinship, M., Gregorevic, P., Chamberlain, J.S., 
Tapscott, S.J. & Storb, R. 2007, "Sustained AAV-mediated dystrophin expression in 
a canine model of Duchenne muscular dystrophy with a brief course of 
immunosuppression", Molecular therapy : the journal of the American Society of 
Gene Therapy, vol. 15, no. 6, pp. 1160-1166. 
Wang, Z., Storb, R., Lee, D., Kushmerick, M.J., Chu, B., Berger, C., Arnett, A., Allen, J., 
Chamberlain, J.S., Riddell, S.R. & Tapscott, S.J. 2010, "Immune responses to AAV 
in canine muscle monitored by cellular assays and noninvasive imaging", Molecular 
therapy : the journal of the American Society of Gene Therapy, vol. 18, no. 3, pp. 
617-624. 
108 
 
Watkins, S.C., Hoffman, E.P., Slayter, H.S. & Kunkel, L.M. 1988, "Immunoelectron 
microscopic localization of dystrophin in myofibres", Nature, vol. 333, no. 6176, pp. 
863-866. 
Welch, E.M., Barton, E.R., Zhuo, J., Tomizawa, Y., Friesen, W.J., Trifillis, P., Paushkin, 
S., Patel, M., Trotta, C.R., Hwang, S., Wilde, R.G., Karp, G., Takasugi, J., Chen, G., 
Jones, S., Ren, H., Moon, Y.C., Corson, D., Turpoff, A.A., Campbell, J.A., Conn, 
M.M., Khan, A., Almstead, N.G., Hedrick, J., Mollin, A., Risher, N., Weetall, M., Yeh, 
S., Branstrom, A.A., Colacino, J.M., Babiak, J., Ju, W.D., Hirawat, S., Northcutt, 
V.J., Miller, L.L., Spatrick, P., He, F., Kawana, M., Feng, H., Jacobson, A., Peltz, 
S.W. & Sweeney, H.L. 2007, "PTC124 targets genetic disorders caused by 
nonsense mutations", Nature, vol. 447, no. 7140, pp. 87-91. 
Wild, F. 1846, "Ueber die peristaltische Bewegung des Oesophagus, nebst einigen 
Bemerkungen uber  diejenigen des Darms.", Z. Rat. Med., vol. 5, pp. 76-132. 
Williams, I.A. & Allen, D.G. 2007, "Intracellular calcium handling in ventricular myocytes 
from mdx mice", American journal of physiology.Heart and circulatory physiology, 
vol. 292, no. 2, pp. H846-55. 
Willis, B.C., Graham, A.S., Wetzel, R. & L Newth, C.J. 2004, "Respiratory inductance 
plethysmography used to diagnose bilateral diaphragmatic paralysis: a case report", 
Pediatric critical care medicine : a journal of the Society of Critical Care Medicine 
and the World Federation of Pediatric Intensive and Critical Care Societies, vol. 5, 
no. 4, pp. 399-402. 
Yamashita, T., Kanaya, K., Kawaguchi, S., Murakami, T. & Yokogushi, K. 2001, 
"Prediction of progression of spinal deformity in Duchenne muscular dystrophy: a 
preliminary report", Spine, vol. 26, no. 11, pp. E223-6. 
Yasuda, S., Kamata, H., Machida, T., Okada, K., Tanaka, A., Suzuki, T., Sadahiro, S. & 
Ohizumi, Y. 2012, "A case of isolated paraaortic lymph node recurrence from colon 
cancer successfully treated with chemoradiotherapy", The Tokai journal of 
experimental and clinical medicine, vol. 37, no. 2, pp. 47-50. 
Yasuda, S., Townsend, D., Michele, D.E., Favre, E.G., Day, S.M. & Metzger, J.M. 2005, 
"Dystrophic heart failure blocked by membrane sealant poloxamer", Nature, vol. 
436, no. 7053, pp. 1025-1029. 
Yokota, T., Lu, Q.L., Partridge, T., Kobayashi, M., Nakamura, A., Takeda, S. & Hoffman, 
E. 2009, "Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy 
dogs", Annals of Neurology, vol. 65, no. 6, pp. 667-676. 
Yost, C.S. 2006, "A new look at the respiratory stimulant doxapram", CNS drug reviews, 
vol. 12, no. 3-4, pp. 236-249. 
Yuasa, K., Nakamura, A., Hijikata, T. & Takeda, S. 2008, "Dystrophin deficiency in 
canine X-linked muscular dystrophy in Japan (CXMDJ) alters myosin heavy chain 
expression profiles in the diaphragm more markedly than in the tibialis cranialis 
muscle", BMC musculoskeletal disorders, vol. 9, pp. 1. 
Yuasa, K., Yoshimura, M., Urasawa, N., Ohshima, S., Howell, J.M., Nakamura, A., 
Hijikata, T., Miyagoe-Suzuki, Y. & Takeda, S. 2007, "Injection of a recombinant AAV 
serotype 2 into canine skeletal muscles evokes strong immune responses against 
transgene products", Gene therapy, vol. 14, no. 17, pp. 1249-1260. 
Yue, Y., Ghosh, A., Long, C., Bostick, B., Smith, B.F., Kornegay, J.N. & Duan, D. 2008, 
"A single intravenous injection of adeno-associated virus serotype-9 leads to whole 
body skeletal muscle transduction in dogs", Molecular therapy : the journal of the 
American Society of Gene Therapy, vol. 16, no. 12, pp. 1944-1952. 
109 
 
Yugeta, N., Urasawa, N., Fujii, Y., Yoshimura, M., Yuasa, K., Wada, M.R., Nakura, M., 
Shimatsu, Y., Tomohiro, M., Takahashi, A., Machida, N., Wakao, Y., Nakamura, A. 
& Takeda, S. 2006, "Cardiac involvement in Beagle-based canine X-linked muscular 
dystrophy in Japan (CXMDJ): electrocardiographic, echocardiographic, and 
morphologic studies", BMC cardiovascular disorders, vol. 6, pp. 47. 
Zamzami, N. & Kroemer, G. 2001, "The mitochondrion in apoptosis: how Pandora's box 
opens", Nature reviews.Molecular cell biology, vol. 2, no. 1, pp. 67-71. 
Zanotti, S., Negri, T., Cappelletti, C., Bernasconi, P., Canioni, E., Di Blasi, C., Pegoraro, 
E., Angelini, C., Ciscato, P., Prelle, A., Mantegazza, R., Morandi, L. & Mora, M. 
2005, "Decorin and biglycan expression is differentially altered in several muscular 
dystrophies", Brain : a journal of neurology, vol. 128, no. Pt 11, pp. 2546-2555. 
Zhou, L. & Lu, H. 2010, "Targeting fibrosis in Duchenne muscular dystrophy", Journal of 
neuropathology and experimental neurology, vol. 69, no. 8, pp. 771-776. 
Zimmer, H.G. 1998, "The Isolated Perfused Heart and Its Pioneers", News 
inphysiological sciences : an international journal of physiology produced jointly by 
the International Union of Physiological Sciences and the American Physiological 
Society, vol. 13, pp. 203-210. 
 
